CURRICULUM VITAE NAME: PAUL RUFF

DATE OF BIRTH: 9th September 1956.

UNIVERSITY OF WITWATERSRAND FACULTY OF HEALTH SCIENCES: CURRENT POSITION: PROFESSOR AND HEAD: Division of Medical Oncology, Department of Medicine, University the of Witwatersrand Faculty of Health Sciences: October 2002 - Date. PREVIOUS POSITIONS: ACTING HEAD: Division of Clinical Haematology and Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences: February 2000 - September 2002. ASSOCIATE PROFESSOR: Division of Clinical Haematology and Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences: January 2001 - September 2002. CHARLOTTE MAXEKE JOHANNESBURG ACADEMIC HOSPITAL: CURRENT POSITION: CHIEF SPECIALIST AND HEAD: Division of Medical Oncology, Department of Medicine, October 2002 - Date. PREVIOUS POSITIONS: PRINCIPAL SPECIALIST AND HEAD: Division of Clinical Haematology and Medical Oncology, Department of Medicine, June 2001 - September 2002. ACTING HEAD: February 2000 - June 2001. Management of solid tumour and haematological malignancies, as well as stem cell transplantation and non-malignant haematology. PRINCIPAL SPECIALIST: Division of Clinical Haematology and Medical Oncology, May 1998 - September 2002.

ACADEMIC QUALIFICATIONS: UNIVERSITY OF THE WITWATERSRAND FACULTY OF HEALTH SCIENCES: 1986: M.Med (Master of Medicine) in Internal Medicine. Dissertation: Nocardial and major fungal infections in renal transplant recipients. 1979: MBBCh (Bachelor of Medicine and Bachelor of Surgery). COLLEGE OF MEDICINE OF SOUTH AFRICA: 2005: FCP (Fellow of College of Physicians) by Peer Review.

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY 1999: ESMO Examination in Medical Oncology, Vienna, Austria 1999: Certified ESMO (European Society for Medical Oncology) Member. Qualifying examination in Medical Oncology in many European countries.

PROFESSIONAL QUALIFICATIONS: SOUTH AFRICA (HPCSA): Medical Practitioner: 1st January 1981. Internal Medicine: 12th May 1986. Medical Oncology: 30th October 1991. UNITED STATES OF AMERICA: Permanent License in Commonwealth of Massachusetts: 1st May 1991. UNITED KINGDOM: Full Registration with the General Medical Council: 22nd May 1981. EUROPE: Certified European Society of Medical Oncology (ESMO) Member: September 1999.

MEMBERSHIP OF PROFESSIONAL SOCIETIES:

U.S.A.: American Society of Hematology (ASH): 1993 - 2010. American Society of Clinical Oncology (ASCO): Since 1995. Europe: European Society of Medical Oncology (ESMO): Since 1996. South Africa: South African Lymphoma Study Group (SALSG): 1992-2004. South African Society of Medical Oncology (SASMO): Since 1988.

CLINICAL EXPERIENCE: HEAD / CHIEF SPECIALIST / MEDICAL ONCOLOGIST: Division of Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences and Johannesburg Hospital. October 2002 - Date. PRINCIPAL SPECIALIST / MEDICAL ONCOLOGIST: Division of Clinical Haematology and Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences and Johannesburg Hospital. May 1998 - September 2002. SENIOR SPECIALIST / MEDICAL ONCOLOGIST: August 1991 - April 1998: Division of Clinical Haematology and Medical Oncology, Department of Medicine, University of Witwatersrand Medical School, Johannesburg and Hillbrow Hospitals.

CLINICAL / RESEARCH FELLOW: July 1988 - June 1991. Department of Biomedical Research and Division of Hematology/Oncology, St Elizabeth's Hospital of Boston, Tufts University School of Medicine, Boston, Massachusetts, USA. Recognised training in Hematology and Medical Oncology for American Board of Internal Medicine (ABIM). SPECIALIST PHYSICIAN: 1.July 1987 - June 1988: Department of Medical Oncology, University of Pretoria and Department of Medicine, No.1 Military Hospital, Thaba Tshwane. 2.January 1986 - June 1987: Division of Haematology/Oncology, Department of Medicine, Hillbrow Hospital and University of Witwatersrand Medical School. MEDICAL REGISTRAR: January 1982 - December 1985: Hillbrow, Johannesburg, Baragwanath and Helen Joseph Hospitals, University of Witwatersrand Medical School. MEDICAL OFFICER: 1981: S.A.D.F. and Benedictine Hospital, Nongoma, Kwazulu-Natal. INTERN: 1980: Johannesburg Hospital.

RESEARCH ACTIVITY: Faculty of Health Sciences (University of Witwatersrand): Most Highly Cited Researcher (2015) South African Medicines Research Council (SAMRC): Principal Investigator of WITS/SAMRC Common Epithelial Cancers Research Centre: Awarded five year grant (2015-2020) to study colorectal, breast and pancreatic cancers in South Africa. National Institutes of Health (NIH) of USA: Co-Principal Investigator (in collaboration with Drs A Neugut and J Jacobson, Columbia University School of Public Health and Dr M Joffe, Wits Health Consortium): Five year grant (2015-2020) to study HIV and breast cancer. Laboratory Basic Science Research in Haematology and Oncology: 1. Cloning, expression and mutations of p55, the major palmitoylated erythrocyte membrane protein containing a PDZ, src homology 3 and guanylate kinase domain (1989-1999). Was the first to identify and clone this novel red cell cytoskeletal protein in 1991 which opened the new field of "Membrane Associated Guanylate Kinases" (MAGUKs) in Cell Biology: Ruff P, Speicher DW and Husain-Chishti A. Molecular identification of a major palmitoylated erythrocyte membrane protein containing the SH-3 (src homology-3) motif. Proceedings of the National Academy of Sciences of the USA 1991; 88: 6595-6599. 2. Ran research laboratory studying mutations in the oestrogen receptor and brca-1 and brca-2 genes in breast cancer with Prof AP MacPhail, Dr R Duarte and Mrs K Amoils. Research funded through Cancer Association and Wits Health Consortium. (2000-2002).

3. Runs research laboratory with Dr C Penny investigating metastasis and angiogenesis in gastrointestinal cancer (Since 2004). Clinical Research in Oncology: Runs JHB ONCOLOGY Syndicate through Wits Health Consortium with active research in many Local and Collaborative Clinical Trials in Oncology: 1. Phase II and III Clinical Trials of novel agents in hepatocellular carcinoma with sorafenib, sunitinib, erlotinib, everolimus, clofazimine, eniluracil, pegylated liposomal doxorubicin and nolatrexed: 1993-2012. 2. Phase I, II and III Clinical Trials with edrocolomab, irinotecan, raltitrexed, eniluracil, capecitabine, oxaliplatin, bevacizumab, aflibercept, sunitinib, panitumumab and cetuximab in Stage C and D colorectal cancer: Since 1996. 3. Phase III Trials with axitinib, gefitinib, erlotinib, vandetanib, topotecan, vinorelbine, pemetrexed, cetuximab, crizotinib, dacomitinib, vorinostat, topotecan, pembrolizumab and bevacizumab in lung cancer: Ongoing since 2000. 4. Phase I, II and III Clinical Trials with interferon-α, Pegasys®, imatinib, nilotinib, & dasatinib in chronic myelogenous leukaemia: Ongoing since 1996. 5. Phase III Clinical Trials with axitinib, S1, tipifarnib and exatecan in pancreatic cancer: 2000-2008. 6. Phase III Clinical Trials with antiemetic agents including 5HT-3 and NK-1 inhibitors: Ongoing since 1992. 7. Phase III Clinical Trials with traztuzumab, docetaxel, zosiquadar, vinflunine, letrozole, lapatinib, tesmelifine, erebulin, neratinib and dexrozoxane in breast cancer: Ongoing since 2002. 8. Phase III Clinical Trials with temsirolimus and everolimus in renal cell cancer: 2003-2010. 9. Phase III Clinical Trials with thalidomide, vorinostat, panobinostat and pembrolizumab in multiple myeloma. 10. Phase III Clinical Trials of pembrolizumab in gastric cancer and head and neck cancer. 11. Phase III Clinical Trials of bevacizumab in cervical cancer. Other Clinical Research Activity: 1. Clofazimine in hepatocellular carcinoma and other malignancies - in collaboration with the Department of Immunology, University of Pretoria: 1993-1999. 2. Interferon-α2b in non-Hodgkin's lymphomas, chronic myeloid leukemia and

multiple myeloma - International Oncology Study Group (IOSG) Protocols: 1994-1998. 3. Founder Member of South African Society of Medical Oncology Clinical Trials Group (SASMO-CTG): 1997-2001. 4. Founder Member of Pan African and Middle Eastern Cooperative Oncology Group (PAMECOG): 1999-2001.

TEACHING AND SUPERVISION OF HIGHER DEGREES: TEACHING: 1. Undergraduate: Teaching to GEMP Medical Students, Division of Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences. 2. Postgraduate: Tutorials, Lectures and Clinical Bedside Teaching to Fellows,

Registrars and Medical Officers, Departments of Medicine and Radiation Oncology, University of Witwatersrand Faculty of Health Sciences. SUPERVISION OF HIGHER DEGREES: 1. Master of Medicine Dissertation Supervisor: Dr Maria Ribeiro, University of Witwatersrand (1994-95; graduating in 1996): "Hormonal therapy of advanced prostate cancer." 2. Doctor of Philosophy Thesis Supervisor (with Dr C Penny): Mrs Karen Amoils, University of Witwatersrand (1999-2011; graduating 2011): "Oestrogen receptor mutations and their influence on breast cancer growth." 3. Doctor of Philosophy Thesis Supervisor (with Dr P Arbuthnot): Mr Luigi Zampieri, University of Witwatersrand (2000-2003; graduating in 2004): "P-glycoprotein expression levels in MCF-7 breast carcinoma cell lines following treatment with tamoxifen & TGF-ß." 4. Master of Medicine Dissertation Supervisor (with Prof B Donde and Dr J Kotzen): Dr Catherine Nyongesa, University of Witwatersrand (2003-2005; graduated with distinction): "Phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy." 5. Doctor of Philosophy Thesis Supervisor (with Dr C Penny): Ms Charleen Rupriah, University of Witwatersrand (2005-2008; graduated 2009). 6. Doctor of Philosophy Thesis Supervisor (with Dr C Penny): Ms Brenda Milner, University of Witwatersrand (2010-2014; graduated 2014). 7. Master of Medicine Dissertation Supervisor: Dr Sze Wai Chan (2011-2014; graduated 2014): “EGFR mutations in lung cancer in South Africa.” 8. Master of Medicine Dissertation Supervisor: Dr D Tshabala (2014-2017): “Chronic Myeloid Leukaemia Treatment at CMJAH 2002-2014.” 9. Doctor of Philosophy Thesis Supervisor (with Dr L Levian and Prof G Candy): Prof C Benn, University of Witwatersrand (2016-). Do margins matter in breast cancer. 10. Master of Science Thesis Supervisor (with Drs S Moch and J Miot): Ms C Herbst, University of Witwatersrand (2015-2017). “Health economics of the chemotherapy of colorectal cancer”. 11. Master of Medicine Dissertation Supervisor: Dr M Debiseng (2016-). Acute myeloid leukaemia in Johannesburg. CLINICAL EXAMINATION CONVENOR AND EXAMINER: College of Medicine Certificate in Medical Oncology: Convenor: September 2002, March 2004, March 2006, September 2007, March 2008, March 2009, September 2009, September 2010, September 2012, September 2014, March 2017. Examiner: September 2004, March 2007, September 2011, March 2014 and September 2015. CLINICAL EXAMINATION CO-ORDINATOR: Fellowship of College of Medicine Clinical Examinations (Hillbrow Hospital): September 1985 and September 1986. EDITORSHIP: Editor-in-Chief, Specialist Medicine: Oncology (2000).

Editorial Board, Specialist Forum (Since 2001). Editor-in-Chief, The Cancer Journal (South African Edition) (2010). Editor-in-Chief, MIMS Oncology (South Africa) (2013). Editor-in-Chief, Journal of Clinical Oncology (South African Edition): 2015-2016. MANUSCRIPT AND ABSTRACT REVIEWER: Reviewer for Journal of Clinical Apheresis (2005). Reviewer for Journal of Thoracic Oncology (2007). Reviewer for Liver International (2007). Abstract reviewer for 2006 UICC (Union Internationale Contra Cancer) Conference. Reviewer for Current Oncology (Canada) (2009 - 2013) Reviewer for European Journal of Cancer (2011) Reviewer for New England Journal of Medicine (2013) Reviewer for World Journal of Surgery (2014) Reviewer for Turkish Journal of Gastroenterology (2014) Reviewer for Chemotherapy (2014-15) Reviewer for Journal of Global Oncology (2015-2017) Reviewer for BMC Cancer (2016) Reviewer for Lancet Gastroenterology and Hepatology (2016) Member of Abstract Review Panel for ASCO Educational Book (2017)

COMMITTEES AND ADMINISTRATION:

University of Witwatersrand: 1. Professor and Head, Division of Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences (Since October 2002). 2. Acting-Head, Division of Clinical Haematology and Medical Oncology, Department of Medicine, University of Witwatersrand Faculty of Health Sciences (February 2000-September 2002). Reorganized and expanded Clinical, Administrative, Teaching and Research Activities of the Division since February 2000. 3. University of Witwatersrand Faculty of Health Sciences Postgraduate Committee (1999 – 2003 and since 2009): Served on Protocol Assessors Groups for Masters and Doctorate Protocols. 4. Wits Health Consortium Management Advisory Board (1999 - 2000). 5. Wits Health Consortium Protocol Review Committee (Since 1999). 6. Executive Committee of Department of Medicine (Since February 2000). 7. University Senate (Since October 2002). 8. Faculty Board (Since October 2002). 9. HE Griffin Grant Selection Committee (Since 2002). 10. HE Griffin Special Cancer Grant Co-ordinator (Since 2003). 11. Department of Medicine Registrar Committee (Since 2005) 12. Wits Health Consortium Executive Committee (Since 2009). Charlotte Maxeke Johannesburg Academic and Hillbrow Hospitals: 1. Head, Division of Medical Oncology, Johannesburg Hospital (Since October 2002). 2. Acting-Head, Division of Clinical Haematology and Medical Oncology, Johannesburg Hospital (February 2000 - September 2002). Reorganised and expanded Clinical, Administrative, Teaching and Research Activities of the Division.

3. Acting-Head, Division of Haematology/Oncology, Hillbrow Hospital (April - Dec 1992). 4. Hillbrow Hospital Pharmacy and Therapeutics Committee (1992 - 1997) 5. Hillbrow Hospital Medical Advisory Committee (1992) 6. Committee of Radiation Control, Johannesburg Hospital (Since 1998) 7. Johannesburg Hospital Pharmacy and Therapeutics Committee (Since 2000) 8. Johannesburg Hospital Medical Advisory Committee (Since 2002) Gauteng Department of Health: Member of Provincial Pharmaceutical and Therapeutics Committee (2015-2016). National Department of Health: 1. Committee on Transplantation in South Africa (2001): Bone Marrow Transplantation Representative. 2. Chairman of Oncology Working Committee on Modernization of Tertiary Health Care Services (2002-2003). 3. Chairman of Expert Committee on Tertiary/Quaternary Essential Drug List (2017, Member since 2007). 4. Ministerial Advisory Committee on Cancer (2013-2016). University of Pretoria: Invited member of Selection Panel for Head of Department of Medical Oncology (2001 and 2005) National Cancer Registry: Chairman of South African National Cancer Registry Scientific Advisory Committee (Since 1998). (Committee Member since 1996). Medicines Control Council of South Africa (MCC): MCC Council Member (2010-2015 and 2015-2020) Chairperson of MCC CTC (Clinical Trials Committee) (2015-2020) Member of MCC CTC (since 2003) Member of MCC CCC (Central Clinical Committee) (2011) Ministerial Advisory Committee on Cancer Control and Prevention (MACC): Member (2013-2016) South African Bone Marrow Registry (SABMR): Member of Inaugural Management Board (2003 - 2010). Cancer Association of South Africa: 1. Cancer Association of South Africa (Johannesburg Branch): Health Promotion Subcommittee and Regional Council (1998 - 2000). 2. Cancer Association of South Africa (Southern Transvaal Branch): Medical Advisory Panel and Education Subcommittee (1994 - 1997). 3. Cancer Association of South Africa Grant Reviewer (Since 2007). 4. Cancer Association of South Africa Research Committee (2007-2010).

South African Oncology Consortium (SAOC): Executive Committee Member (2005-2007) South African Society of Medical Oncology (SASMO): 1. Chairman of Executive Committee of South African Society of Medical Oncology (SASMO) (2008-2013) (Executive Committee Member 1997-2015). 2. South African Society of Medical Oncology Representative on South African Medical Association (SAMA) Private Practice Committee (1998-2000). 3. Congress Co-Convenor - Eighth Congress of South African Society of Medical Oncology, Sea Point, Cape Town (September 1998). 4. Congress Organising Committee (Abstract Coordinator) - Fifth Congress of South African Society of Medical Oncology, Riverside Sun, Vanderbijlpark (October 1993). 5. Congress Organising Committee (Scientific and Abstract Sub-Committee) - Tenth Congress of SASMO, Misty Hills, Muldersdrift (September 2001). 6. Congress Co-Convenor - Eleventh Congress of South African Society of Medical Oncology, Bloemfontein (March 2003). 7. Congress Co-Convenor - Thirteenth Congress of South African Society of Medical Oncology, Drakensberg (March 2007). 8. Congress Co-Convenor - Fifteenth Congress of South African Society of Medical Oncology, Sun City (August 2011). South African Lymphoma Study Group (SALSG): Congress Convenor - 12th Congress of South African Lymphoma Study Group, Sea Point, Cape Town (September 1998). Council for Medical Schemes: Head of PMB Committee for Oncology (2009-2010) National Research Foundation (NRF): Five year Review Panel for South African Research Chair Initiative (2011). American Society of Clinical Oncology (ASCO): Member of ASCO International Affairs Committee (IAC) (2013 – 2016). Editor of South African Edition of Journal of Clinical Oncology (2015 - 2016) Invited Faculty Member and Sessional Chair, 35th Annual Meeting of American Society of Clinical Oncology (2016). Member of ASCO International Clinical Trials Workshop (ICTW) (2015-2018) Member of ASCO Educational Book Review Panel (2017) World Health Organization (WHO): UICC Review of the World Health Organization’s Model List of Essential Medicines for Cancer: Acute Myeloid Leukemia Regimen Document Author (2014-2016)

PEER REVIEWED PUBLICATIONS: 1982: 1. Brennan MJ, Ruff P and Sandyk R. Efficacy of a combination of sodium valproate and baclofen in Meige's disease (idiopathic orofacial dystonia). British Medical Journal 1982; 285: 853.

1985: 2. Lewis M, Kallenbach J, Ruff P, Zaltsman M, Abramowitz J and Zwi S. Invasive pulmonary aspergillosis complicating influenza A in a previously healthy patient. Chest 1985; 87: 691-693. 1987: 3. Sacho H, Klugman KP, Koornhof HJ and Ruff P. Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus. Journal of Infection 1987; 14: 188-189. 4. Keene P, Mendelow B, Pinto MR, Bezwoda WR, Falkson G, Ruff P, McDougall L and Bernstein R. Abnormalities of chromosome 12p13 and malignant proliferation of eosinophils - a non-random association. British Journal of Haematology 1987; 67: 27-31. 1989: 5. Ruff P, Bagg A and Papadopoulos K. Precursor T-cell lymphoma associated with HIV-1 infection. Cancer 1989; 64: 39-42. 6. Ruff P, Derman DP, Weaving A and Bezwoda WR. Sequential hormonal therapy and sequential hormonal and chemo-therapy for advanced prostatic cancer. Oncology 1989; 46: 288-292. 1990: 7. Lambert S, Yu H, Prchal J, Lawler J, Ruff P, Speicher DW, Cheung MC, Kan YW and Palek J. cDNA sequence for human erythrocyte ankyrin. Proceedings of the National Academy of Sciences of the USA 1990; 87: 1730-1734. 1991: 8. Husain-Chishti A and Ruff P. Malaria and ovalocytosis - molecular mimicry? Biochimica et Biophysica Acta 1991; 1096: 263-264. 9. Ruff P, Speicher DW and Husain-Chishti A. Molecular identification of a major palmitoylated erythrocyte membrane protein containing the SH-3 (src homology-3) motif. Proceedings of the National Academy of Sciences of the USA 1991; 88: 6595-6599. 1993: 10. Bezwoda WR, Seymour L and Ruff P. Combined cytosine arabinoside plus interferon-alpha. II: Clinical studies in leukemia and lymphoma. International Journal of Oncology 1993; 2: 469-472. 11. Rana AP, Ruff P, Maalouf GJ, Speicher DW and Chishti AH. Cloning of human erythroid dematin reveals another member of the villin family. Proceedings of the National Academy of Sciences of the USA 1993; 90: 6651-6655. 12. Stein ME, Lakier R, Kuten A, Spencer D, Ruff P and Bezwoda WR. Radiation therapy in endemic (African) Kaposi's sarcoma. International Journal of Radiation Oncology and Biological Physics 1993; 27: 1181-1184. 1994: 13. Stein ME, Spencer D, Ruff P, Lakier R, MacPhail AP and Bezwoda WR. Endemic African Kaposi's Sarcoma - Clinical and Therapeutic Implications. Oncology 1994; 51: 63-69

14. Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R, Butcher M, Foster J and McQuade B. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology 1994; 51: 113-118. 15. Stein M, Kantor A, Spencer D, Lakier R, Ruff P and Dale J. Radiation therapy in an elderly African population with Kaposi's sarcoma. Tumori 1994; 80: 139-140. 16. Stein ME, Spencer D and Ruff P. Lymphoproliferative malignancies in association with endemic African Kaposi's sarcoma - a retrospective study. Central African Journal of Medicine 1994; 40: 176-178. 17. Stein ME, Spencer D, Kantor A, Ruff P, Haim N and Bezwoda WR. Epidemic AIDS-related Kaposi's sarcoma in southern Africa: experience at the Johannesburg General Hospital (1980-1990). Transactions of the Royal Society of Tropical Medicine and Hygiene 1994; 88: 434-436. 1995: 18. Ruff P, Saragas E, Poulos M and Weaving EA. Patterns of clonal evolution in transformed chronic myelogenous leukemia. Cancer Genetics and Cytogenetics 1995; 81: 182-184. 1996: 19. Panz VR, Ruff P, Joffe BI, Kedda M-A and Seftel HC. SSCP analysis of the tyrosine kinase domain of the insulin receptor gene: Polymorphisms detected in South African black and white subjects. Human Genetics 1996; 97: 438-440. 20. Stein ME, Ruff P, Weaving A, Fried J and Bezwoda WR. A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma in young blacks in southern Africa. American Journal of Clinical Oncology 1996; 19(4): 386-388. 21. Ruff P, Grimm EE and Kim A. Molecular analysis of a silent polymorphism in the PDZ domain of p55, the major palmitoylated erythrocyte membrane protein. Hematopathology and Molecular Hematology 1996; 10(4): 187-191. 1997: 22. Stein ME, Ruff P, Drumea K and Bezwoda WR. Undifferentiated Nasopharyngeal Carcinoma: Pattern of Failure - Experience at the Johannesburg Hospital (1989-1994). Oncology 1997; 54(4): 348-349. 23. Sitas F, Bezwoda WR, Levin V, Ruff P, Kew MC, Hale MJ, Carrara H, Beral V, Fleming G, Odes R and Weaving A. Association between human immunodeficiency virus type 1 and cancer in the black population of Johannesburg and Soweto, South Africa. British Journal of Cancer 1997; 75(11): 1704-1707. 24. Ribeiro M, Ruff P and Falkson G. Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. American Journal of Clinical Oncology 1997; 20(6): 605-608. 1998: 25. Ruff P, Chasen MR, Long JEH and van Rensburg CEJ. A phase II study of oral clofazimine in unresectable and metastatic hepatocellular carcinoma. Annals of Oncology 1998; 9(2): 217-219. 1999: 26. Ruff P, Kim A, Grimm E, Bischoff D and Chishti AH. Exon skipping truncates the

PDZ domain of human erythroid p55 in a patient with chronic myeloid leukemia in acute megakaryoblastic blast crisis. Leukemia Research 1999; 23(3): 247-250. 27. Davidson N, Rapoport B, Erikstein B, L'Esperance B, Ruff P, Paska W,Miller I and Curtis P. Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Clinical Therapeutics 1999; 21(3): 492-502. 28. Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, Jentsch U, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff C, Weiss R, Patel M, Ruff P, Bezwoda WR, Hale M and Retter E. The seroepidemiology of HHV/KSHV in a large population of black cancer patients in South Africa. New England Journal of Medicine 1999; 340(24): 1863-1871. 2000: 29. Sitas F, Pacella-Norman R, Carrara H, Ruff P, Patel M, Sur R, Rowji P, Jentsch U, Saffer D, Connor M, Beral V, Bull D and Newton R. The spectrum of HIV-1 related cancers in South Africa. International Journal of Cancer 2000; 88(3): 489-492. 30. Giles FJ, Shan J, Advani SH, Akan H, Aydogdu I, Aziz Z, Azim HA, Bapsy PP, Buyukkececi F, Chaimongkoi B, Chen PM, Cheong SK, Ferhanoglu B, Hamza R, Khalid HM, Intragumtornchai T, Kim SW, Kim SY, Koc H, Kumar L, Kumar R, Lei KI, Lekhakula A, Muthalib A, Patel M, Poovalingam VP, Prayoonwiwat W, Rana F, Reksodiputro AH, Ruff P, Sagar TG, Schwarer AP, Song HS, Suh CW, Suharti C, Supindman I, Tee GY, Thamprasit T, Hillalon A, Wickham NR, Wong JE, Yalcin A and Jootar S. A prospective randomised study of CHOP versus CHOP plus alpha-2b interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: The International Oncology Study Group NHL-1 study. Leukemia and Lymphoma 2000; 40(1-2): 95-103. 2001: 31. Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I and Peachey M. A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma. European Journal of Cancer 2001; 37(11): 1352-1358. 32. Abratt RP, Vorobiof DA, Goedhals L, Rapoport BL, Ruff P and Slabber CF. Scientific fraud and international research. Journal of Clinical Oncology 2001; 19(15): 3592. 33. Vorobiof DA, Abratt R, Rapoport B, Ruff P, Slabber C and Goedhals L. Scientific misconduct in cancer clinical trials. S A Medical Journal 2001; 91(8): 614-615. 2002: 34. Pacella-Norman R, Urban MI, Sitas F, Carrara H, Sur R, Hale M, Ruff P, Patel M, Newton R, Bull D and Beral V. Risk factors for oesophageal, lung, oral and laryngeal cancers in black South Africans. British Journal of Cancer 2002; 86(11): 1751-1756. 35. Zampieri L, Bianchi P, Ruff P and Arbuthnot P. Differential modulation by estradiol of P-glycoprotein drug resistance protein in cultured MCF7 and T47D breast cancer cells. Anticancer Research 2002; 22(4): 2253-2259. 2003: 36. Levine AM, Hancock BW, MacPhail P, Ruff P and Ashcroft RE. Forum: The treatment of AIDS-related cancers. Lancet Oncology 2003; 4: 576-581.

37. Wojcicki J, Newton R, Urban M, Stein L, Hale M, Patel M, Ruff P, Sur R and Sitas F. Risk factors for high HHV-8 antibody titres in black HIV-1 negative South African cancer patients. BMC Infectious Diseases 2003; 3: 21. 2004: 38. Ruff P. Therapeutic options in hepatocellular carcinoma. American Journal of Cancer 2004; 3(2): 119-131. 39. Kuehr T, Ruff P, Rapoport B, Falk S, Daniel F, Jacobs C, Davidson N, Thaler J, Boussard B, and Carmichael J. Phase I/II study of irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule first line patients with advanced colorectal cancer. BMC Cancer 2004; 4: 36. 40. Wojcicki J, Newton R, Urban M, Stein L, Hale M, Patel M, Ruff P, Sur R, Sitas F. Low socioeconomic status and risk for infection with human herpes virus 8 among HIV-1 negative South African black cancer patients. Epidemiol Infect 2004; 132(6): 1191-1197. 2005: 41. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, Tomiak E, Al-Tweigeri T, Chap L, Juhos E, Guevin R, Howell A, Fornandez T, Hainsworth J, Coleman R, Viholes J, Modiano M, Pinter T, Tang SC, Colwell B, Prady C, Provencher L, Walde D, Rodriguez-Lescure A, Hugh J, Loret C, Rupin M, Blitz S, Jacobs P, Murawsky M, Riva A, Vogel C, Guixa H, Mickiewicz E, Martinez J, Sculler J, Teixeira L, Gelmon K, Sehdev S, Drolet Y, Dufresne J, Yelle L, Zibdawi L, Lesperance B, Verma S, Cantin J, Holland D, Trudeau M, Chang J, Rubin S, Allan S, Abrahamova J, Finek J, Abd-el-Azim H, Gad-el-Mawla N, Oberhoff C, Georgoulias V, Szanto K, Ruff P, Pelegri A, Alba E, Alvarez I, Aranda E, Munnariz B, Anton A, Lobo, F, Lopez-Vega JM, Menendez MD, Murias A, Cassinello J, Garcia-Puche JL, Nylen U, Whipp E, LeVay J, Erban J, Graham B, Harris L, O’Rourke M, Beck T, Limentani S, Robert N, Tongol J, Schnell F, Begas A, Kerns R, Rosenberg A, Campos L, Foster J, Beeker T, Iannotti N, George C, Avery B, Viola A and Garbino C. Adjuvant docetaxel for node-positive breast cancer. New England Journal of Medicine 2005; 352(22): 2302-2313. 2006: 42. Nyongesa C, Ruff P, Donde B and Kotzen J. A phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy. International Journal of Gynecological Oncology 2006; 16: 1614-1619. 43. Woodward V, Penny C, Ruff P and Strkalj G. Intercondylar fossa of the femur: a novel region for DNA extraction. South African Archaeological Bulletin 2006; 61(183): 96-97. 44. Berrington de Gonzalez A, Urban M, Sitas F, Blackburn N, Hale M, Patel M, Ruff P, Sur R, Newton R and Beral V. Antibodies against six human herpes viruses in relation to seven cancers in black South Africans: A case control study. Infectious Agents and Cancer 2006 Sep 14; 1: 2. 2007: 45. Ruff P. Targeted therapy in cancer in 21st century. South African CME Journal 2007; 25(2): 77-78. 46. Jacobs P, Ruff P, Wood L, Moodley D and Mansvelt E. Amyloidosis: A changing clinical perspective. Hematology 2007; 12(2): 163-167.

47. Gish R, Porta C, Lazar L, Ruff P, Feld R, Croitoru A, Feun L, Krzysztof J, Leighton J, Gallo J and Kennealey G. Results of a Phase III randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatexed (NOL) or doxorubicin (DOX). Journal of Clinical Oncology 2007; 25(21): 3069-3075. 48. Jacobs P, Wood L and Ruff P. Hodgkin’s Lymphoma in Developing Countries: An African Perspective with a Note on Asia and Latin America in Hodgkin’s Lymphoma (2nd Edition); Hoppe RT, Mauch PM, Armitage JO, Diehl V and Weiss LM (editors). Lippincott Williams and Wilkins; Philadelphia 2007; Chapter 30: 427-448. 2008: 49. Stein L, Urban M, O’Connell D, Yu XQ, Beral V, Newton R, Ruff P, Donde B, Hale M, Patel M and Sitas F. The spectrum of human immunodeficiency virus-associated cancers in South Africa: results from a case control study, 1995-2004. International Journal of Cancer 2008; 122: 2260-2265. 50. Sonneveld P, Hajek R, Nagler A, Spencer A, Bladé J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ, Berares R, Labanca V, Orlando S, Sanchez Avalos J, Herrmann H, Hertzberg M, Horvath N, Joshua D, Ma D, Roberts A, Ward C, Drach J, Gisslinger H, Greil R, Gunsilius E, Linkesch W, Ludwig H, Thaler J, Delforge M, Doyen C, Janssens A, Noens L, Schots R, Belch A, Delage R, Kouroukis T, Roy J, Sutherland H, Van der Jagt R, Scudla V, Spicka I, Attal M, Benboubker L, Casassus P, Divine M, Facon T, Haioun C, Hulin C, Hunault M, Michallet M, Boccadoro M, Castoldi G, Dammacco F, Foa R, Rodeghiero F, Ben-Yehuda D, Berrebi A, Hardan I, Mittelman M, Naperstek E, Roth B, Rowe J, Ruchlamer R, Shpilberg O, Winder A, Biesma D, Kersten M, Lokhorst H, Ossenkoppele G, Raymakers R, Segeren C, Vellenga E, Wijermans P, Wittebol S, Browett P, Dmoszynska A, Hellmann A, Jedrzejczak W, Kloczko J, Kuliczkowski K, De Lacerda J, Esteves G, Teixeira A, Teixeira P, Abdulkadyrov K, Alexeeva J, Biakhov M, Domnikova N, Dunaev Y, Golenkov A, Khuageva N, Loginov A, Osmanov E, Pavlov V, Rukavitsyn O, Samoilova O, Suvorov A, Ming Fook M, Yeow G, Alegre A, Garcia L, Lahuerta J, San Miguel J, Cohen G, Jacobs P, Louw V, Novitzky N, Patel M, Rapoport B, Ruff P, Rahemtulla A, Yong K, Singer C, Yong K, Ansari R, Berdeja J, Berryman B, Brown A, Butler F, Caggiano V, Catlett J, Dainer P, Del Prete S, Fung H, Fehrenbacher L, Ferguson S, Frank R, Fu C, Glass J, Gurtler J, Hainsworth J, Hanna W, Harrer G, Henry D, Holladay C, Howard D, Jacobson R, Jaroonwanichkul P, Karamlou D Khaira D, Lee K, Limentani S, Moezi M, Mohrbacher A, Morrison V, Patel D, Phelan J, Richter H, Rifkin R, Rizzieri D, Saleh M, Schiller G, Shadduck R, Shiba D, Siegel D, Silverman M, Swanson P, Tuscano J, Vescio R, Walters T, Wolf J, Zrada S. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 2008; 112(7): 1529-1537. 51. Stein L, Urban M, Weber M, Ruff P, Hale M, Donde B, Patel M and Sitas F. Effects of tobacco smoking on cancer and cardiovascular disease in a black population of urban South Africa. British Journal of Cancer 2008; 98(9): 1586-1592. 52. Ruff P, Schlaphoff T, du Toit E and Heyns A. The South African Bone Marrow Registry and the Development of Allogeneic Bone Marrow Transplantation in South Africa. South African Medical Journal 2008; 98(7): 516-520. 53. Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R, Cihon F, Anderson S, Shah S, Bukowski R, Escudier B, Blajman C, Fein L, Martín C, Taber R,

Boyer M, Davis I, Gurney H, Hovey E, Leong D, Steer C, DeGreve J, Gil T, Barrios C, David W, Skare NG, Notari A, Schwartsmann G, Gunnar N, Ernst S, Hotte S, Miller W, Moore M, North S, Fodor M, Caty A, Chevreau C, Duclos B, Gravis G, Negrier S, Oudard S, Ravaud A, Rolland F, Sevin E, Grimm MO, Gschwend J, Heinzer H, Jäger E, Krause S, Michel MS, Rohde D, Siebels M, Siegsmund M, Staehler M, Wirth M, Baki M, Bodrogi I, Cseh J, Ruzsa A, Toth C, Ben-Yosef R, Gez E, Bajetta E, Boni C, Bracarda S, Cognetti F, Conte P, Porta C, Spronsen DJ, Blasinka-Morawiec M, Demkow T, Lorenz J, Mazurkiewicz M, Rolski J, Sikorski A, Solska E, Tomczak P, Bolotina L, Karlov P, Karyakin O, Khasanov R, Lichinitser M, Lubennikov V, Moiseenko V, Sherman N, Abratt R, Coetzee L, Cohen G, Heyns C, Jordaan J, Ruff P, Wentzel S, Bellmunt J, Climent MA, González JL, López G, Bashtan V, Dumamsky Y, Klimenko I, Pilipenko N, Shparik Y, Hawkins R, McMenemin R, Nathan P, Porfiri E, Savage P, White J, Anderson C, Bains Y, Bleickardt E, Bradof J, Brooks D, Cardi G, Cervera A, Davis N, Desai A, Drabkin H, Dudek A, Dutcher J, Formanek G, Gabrail N, Gross H, Haung Y, Henderson C, Hutson T, Jonasch E, Lara P, McCracken J, McDermott D, Mena R, Middleton R, Petrylak D, Picus J, Quinn D, Rausch P, Rinaldi D, Ryan C, Tchekmedyian N, Vuky J, Charnick S, Crowley-Nowick P, Erlick N. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008 Oct 15; 100(20):1454-63. 2009 54. Gibbon V, Paximadis M, Strkalj G, Ruff P and Penny C. Novel methods of molecular sex identification from skeletal tissue using the amelogenin gene. Forensic Science International: Genetics 2009; 3: 74-79. 55. Ruff P, Vorobiof DA, Jordaan JP, Demetriou GS, Moodley SD, Nosworthy AL, Werner ID and Raats J. A randomized placebo-controlled, double-blind phase 2 study of docetaxel compared to docetaxel plus zosuquidar in women with metastatic or locally recurrent breast cancer (BC) who have received one prior chemotherapy regimen. Cancer Chemotherapy and Pharmacology 2009; 64: 763-768. 56. Van Cutsem E, Kohne CH, Hitre E, Zaluski J, Chang Chien C-R, Makhson A, D’Haens G, Pintér T, Lim R, Bodoky G, Jae Kyung Roh , Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J and Rougier P. FOLFIRI with and without cetuximab in the first-line treatment of metastatic colorectal cancer: efficacy, safety and KRAS analysis. New England Journal of Medicine 2009; 360: 1408-1417. 57. Gibbon V, Penny C, Strkalj G and Ruff P. Minimally invasive bone sampling method for DNA analysis. American Journal of Physical Anthropology 2009; 139(4): 596-599. 2010 58. Gibbon VE, Strkalj G, Paximadis M, Ruff P and Penny CB. The sex profile of skeletal remains from a cemetery of Chinese indentured labourers in South Africa. South African Journal of Science 2010; 106(7/8) (Art #191): 65-68. 59. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner K, Wolf M and Gansert J.

Randomized, phase 3 study (PRIME) of panitumumab with FOLFOX4 versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer. Journal of Clinical Oncology 2010; 28(31): 4697-4705. 60. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A,

Larson RA, Kantarjian HM; Moiraghi B, Perez M, Greil R, Valent P, Bosly A, Martiat P, Noens L, André M, Verhoef G, Conchon M, Souza C, Nonino A, Hungria V, Zanichelli MA, Colturato V, Forrest D, Lipton JH, Savoie ML, Delage R, Lalancette M, Quintero G, Gomez M, Klamova H, Faber E, Bjerrum OW, Fredriksen H, Vestergaard H, Marcher C, Kamel H, Elzawam H, Porkka K, Remes K, Reiffers J, Guilhot F, Facon T, Tulliez M, Guerci-Bresler AP, Nicolini FE, Charbonnier A, Rea D, Johnson-Ansah A, Legros L, Harousseau JL, Rigal-Huguet F, Escoffre M, Gardembas M, Guyotat D, Cahn JY, Gattermann N, Ottmann O, Niederwieser D, Stegelmann F, Schafhausen P, Brümmendorf T, Duyster J, Blumenstengel K, Scheid C, Kneba M, Kwong YL, Masszi T, Petrini M, Alimena G, Di Raimondo F, Rosti G, Rotoli B, Pane F, Pungolino E, Amadori S, Abruzzese E, Fioritoni G, Lauria F, Bosi A, Martelli M, Rambaldi A, Ferrara F, Nobile F, Gobbi M, Carella AM, Orlandi EM, Leoni P, Tiribelli M, Levis A, Imamura M, Takahashi N, Tsukamoto N, Chiba S, Nagai T, Okamoto S, Miura O, Kurokawa M, Ohnishi K, Toba K, Nakao S, Tomita A, Miyamura K, Hino M, Maeda Y, Kimura A, Kawaguchi T, Miyazaki Y, Nakaseko C, Jinnai I, Matsuda A, Matsumura I, Ishikawa J, Ohyashiki K, Okada M, Usuki K, Kobayashi Y, Ohishi K, Imai K, Miyawaki S, Kanda Y, Park SY, Kim HJ, Sohn SK, Lee KH, Jung CW, Ong TC, Gómez Almaguer D, Kassack J, Ossenkoppele GJ, Gedde-Dahl T, Hjorth-Hansen H, Jedrzejczak W, Dmoszynska A, Starzak-Dwozdz J, Holowiecki J, Kyrcz-Krzemieñ S, Kuliczkowski K, Zaritsky A, Turkina A, Pospelova T, Goh YT, Koh LP, Demitrovicova L, Mistrik M, Ruff P, Louw V, Dreosti LM, Novitzky N, Cohen G, Cervantes F, Cañizo C, de Paz R, del Castillo S, Perez Encinas M, Sanz Alonso M, Marin F, Pérez-López R, Hernandez Boluda J, Echeveste Gutierrez MA, Odriozola J, Herrera P, Steegman JL, Conde E, Lopez P, Giraldo P, Boque C, Heredia B, Font AJ, Rodriguez RF, Rodriguez MJ, Batlle J, Stenke L, Lehmann S, Wadenvik H, Simonsson B, Markevärn B, Själander A, Richter J, Bjoreman M, Eriksson KM, Chalandon Y, Shih LY, Yao M, Wang MC, Jootar S, Bunworasate U, Ulkü B, Haznedar R, Undar B, Sahin B, Marin D, Smith G, Byrne J, Holyoake T, Kalaycio M, Akard L, Heaney M, Al-Janadi A, Goldberg S, Powell B, Harker WG, Shea T, Gingrich R, Glass J, Paquette R, Siegrist C, Woodson M, Fehrenbacher L, Koh H, Flinn I, Arrowsmith E, Ervin T, Guerra M, Wallach H, Berry W, Burke J, Edenfield W, Guzley G, Davis J, Richards D, Schlossman D, Kolibaba K, Alemany C, Savin M, Robbins G, Lopez J, Goldman JM, Camm J, Schiffer CA, Sargent DJ. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; Jun 17; 362(24): 2251-9. 2011 61. Vorobiof DA and Ruff P. Cancer in South Africa and the Role of the National Cancer Registry. The ASCO Post 2011; 2(7).

62. Louw V, Dreost L, Ruff P, Jogessar V, Moodley D, Novitzky N and Willem P.

Guideline: Recommendations for the management of adult chronic myeloid

leukaemia in South Africa. South African Medical Journal 2011; 101(11): 840-846. 63. Louw V, Bassa F, Chan SW, Dreosti L, du Toit M, Ferreira M, Gartrell F, Gunther K, Jogessar V, Littleton N, Mahlangu J, McDonald A, Patel M, Pool R, Ruff P, Schmidt A, Sissolak G, Swart A, Verburgh E and Webb M. Guideline for the treatment of myelodysplastic syndromes (MDS) in South Africa. South African Medical Journal 2011; 101(12): 900-906. 2012 64. Abratt RP, Dreosti L and Ruff P. Cancer care in South Africa. Lancet Oncology

2012; 13(8): 324. 65. van Cutsem E, Tabernero J, Lakomi R, Prenen H, Prausona J, Macarulla T, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J and Allegra C. Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR). Journal of Clinical Oncology 2012; 30: 3499-3506. 2013 66. Penny CB, Milner, BL, Gibbon VE, Ruff P. The HT29 and DLD-1 colon cancer cell lines contain cancer stem cells. Clinical Anatomy 2013. Published online: 3 Apr 2013. DOI: 10.1002/ca.22235 67. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment in wild- type RAS metastatic colorectal cancer. N Engl J Med 2013; 369: 1023-1034. 2014 68. Tabernero J, van Cutsem E, Lakomi R, Prausona J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J, Soussan-Lazard K, Chevalier S and Allegra C. Aflibercept versus placebo in combination with FOLFIRI in the treatment of previously treated metastatic colorectal cancer: Prespecified subgroup analyses from the VELOUR Trial. European Journal of Cancer 2014; 50: 320-331. 69. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel E, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Canon J-L, Rother M, Oliner KS, Wolf M and Gansert J.

Final results from PRIME: Randomized phase 3 study of panitumumab (pmab) with FOLFOX4 for 1st-line metastatic colorectal cancer (mCRC). Annals of Oncology 2014; 25: 1346–1355. 70. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappan S and Sidhu R. Panitumumab Versus Cetuximab in Patients With Metastatic Colorectal Cancer. Lancet Oncology 2014; 15(7): 569-579. 71. Price TJ, Peeters M, Ruff P, Murugappan S and Sidhu R. ASPECCT: panitumumab versus cetuximab for colorectal cancer ? Authors' reply. Lancet Oncology 2014; 15: e303. 72. Singh E, Sengayi M, Urban M, Babb C, Kellett P and Ruff P. The South African National Cancer Registry: an update. Lancet Oncology 2014; 15: e363.

2015 73. Ruff P , Ferry DR, Lakomy R, Prausova J, van Hazel GA, Hoff PM, Cunningham D, Arnold D, Schmoll H, Moisyenko VM, McKendrick JJ, Ten Tije AJ, Vishwanath RL, Bhargava P, Chevalier S, Tabernero J and van Cutsem E. Long term efficacy and safety of aflibercept in combination with FOLFIRI in patients with mCRC who progressed on previous oxaliplatin-based therapy. European Journal of Cancer 2015; 51: 18-26. 74. Singh E, Ruff P , Babb C, Sengayi M, Beery M, Khoali L, Kellett P and Underwood JM. Establishment of a Cancer Surveillance Program in a Developing Country: The South African Experience. Lancet Oncology 2015; 16(8): e14-21.

75. Milner BL, Penny CB, Gibbon VE, Kay P and Ruff P. Cancer Stem Cell Markers of Tumour Stage in Colorectal Cancer Cells. Journal Tissue Science Engineering 2015; 6(1): 1-4. 76. van Cutsem E, Joulain F, Hoff P, Mitchell E, Ruff P, Lakomy R, Prausova J, Moiseyenko V, Van Hazel G, Cunningham D, Arnold D, Schmoll H, ten Tije A, McKendrick J, Kroening H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath R, Macarulla T, Allegra C, Tabernero J. Aflibercept/FOLFIRI vs Placebo/FOLFIRI in second line Metastatic Colorectal Cancer: A post Hoc Analysis of Survival in the phase III VELOUR study Subsequent to Exclusion of Patients Who Had Recurrence During or Within 6 Months of Completing only Adjuvant Oxaliplatin-Based Therapy. Targeted Oncology 2015 (epub December 26). 2016 77. Moodley J, Stefan DC, Sewram V, Ruff P, Singh S, Asante-Shongwe K and Freeman M. Current cancer research in South Africa. South African Medical Journal 2016 May 10; 106(6): 607-610. doi: 10.7196/SAMJ.2016.v106i6.10314. 78. Ruff P, al-Sukhun S, Blanchard C and Shulman LN. Access to Cancer Therapeutics in Low- and Middle-Income Countries. American Society of Clinical Oncology Educational Book 2016; 35: 58-65. doi: 10.14694/EDBK_155975 www.asco.org/edbook. 79. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Hoang T and Hei Y. Final Results From ASPECCT: Randomized Phase 3 Noninferiority Study of Panitumumab Versus Cetuximab in Chemorefractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. European Journal of Cancer 2016 Nov; 68: 51-59. doi: 10.1016/j.ejca.2016.08.010. 80. Siena S, Tabernero J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Demonty G, Hechmati G and Douillard JY. Quality of life during first-line treatment with FOLFOX4 with or without panitumumab in RAS wild-type metastatic colorectal carcinoma. ESMO Open 2016 Mar 31; 1(2): e000041. 81. Cubasch H, Ruff P, Joffe M, Norris SA, Chirwa T, Nietz S, Sharma V, Duarte R, Buccimazza I, David R, Cacala S, Stopforth LW, Tsai WY, Stavsky E, Crew K, Jacobson JS and Neugut AI. The South African Breast Cancer and HIV Outcomes (SABCHO) Study: A multi-center cohort study of HIV and breast cancer in sub-Saharan Africa. DOI: 10.1200/JGO.2015.002675 Journal of Global Oncology - published online before print October 28, 2016. 2017 82. Singh E, Joffe M, Cubasch H, Ruff P, Norris SA and Pisa PT. Breast cancer patterns and trends differ by ethnicity: A report from the pathology-based South African National Cancer Registry (1994–2009). European Journal of Public Health 2017 Feb 1; 27 (1): 173-178. doi:10:1093/eurpub/ckw191. 83. Ruff P, van Cutsem E, Lakomý R, Prausova J, van Hazel GA, Moiseyenko VM, Soussan–Lazard K, Dochy E, Macarulla T and Papamichael D. Observed Benefit of Aflibercept in Elderly Patients with Metastatic Colorectal Cancer Aged 65 Years and Older: A Prespecified Age-Based Analysis from the Randomized Placebo-Controlled Phase III VELOUR Trial. Journal of Geriatric Oncology 2017 (submitted). 84. Logan TF, Szczylik C, Tannir N, Benedetto P, Makhson A, McDermott D, Ruff P, Mikulás J, Dutcher JP, Berkenblit A, Galand L, Krygowski M and Hudes G. Effect of Nephrectomy Status on Temsirolimus Efficacy in Patients with Advanced Poor-Prognostic Renal Cell Cancer. Medical Oncology 2017; (submitted).

85. Herbst C, Miot J, Moch S and Ruff P. Cost Analysis of Colorectal Cancer Chemotherapy in a South African Public Healthcare Sector Patient Cohort. European Journal of Cancer Care 2017 (submitted) ORAL PRESENTATIONS AT CONFERENCES: International Meetings: 1. Ruff P, Stein M and Weaving EA. (1994) Cisplatin and ifosphamide in advanced poorly differentiated carcinoma of the nasopharynx. Satellite Symposium: Treatment of Head and Neck Cancer - Is there a Role for Ifosfamide? at 16th International Cancer Congress (New Delhi, India) 2. Ruff P, Chasen MR, Long JEH and van Rensburg CEJ. (1996) Phase II study of clofazimine in advanced unresectable hepatocellular carcinoma (HCC). 1996 Shanghai International Symposium on Liver Cancer and Hepatitis (Shanghai, China). 3. Giles FJ, Tian G, Chang NB, Wang SH, Villalon A, Bapsy PP, Chaimongkol B, Raafat J, Jootar S, Harryanto A, Taratom T, Sagar TG, Kim SW, Suh C, Esfahani F, Schwarer AP, Muthalib A, Song HS, Suharti C, Rapoport B, Lekhakula A, Kuchopillai V, Kim SY, Kumar R, Haron MR, Wickham NR, Intragumtornchai T, Kannan T, Cheong SK, Voges CV, Coccia-Portugal MA, Lee KB, Bellarmine L, Serdengecti S, Soyeun O, Smruti BK, Shah PM, Sotamaphan N, Jinarantana V, Aziz Z, Chuncharunee S, Prayoonwiwat W, Lim A, Leong KW, Lam KS, Leong KW, Lam KS, Ho BS, Ruff P, Kusuanco DA and Franco MM. (1996) Initial characteristics of Chinese patients on the International Oncology Study Group (IOSG) NHL1 study. First National Congress of Hematological Oncology (Beijing, China). 4. Giles F, Tian D, Chen S, Ru JY, Chen YC, Tien HF, Chang JY, Ho CH, Chao TY, Wang PN, Wickham NR, Akan H, Raafat J, Uskent N, Supandiman I, Ruff P, Suharti C, Suh C, Muthalib A, Tan P, Kochupillai V, Rapoport BL, Lee KB, Parikh PM, Salim KA, Harryanto A, Radheshyam D, Sagar TG, Lekhakula A, Thamprasit T, Kang JH, Suwansela S, Smurti BK, Kim SY, Anggraeni E, Sumantri R, Ragnuhardi D, Gonzaga M, Gopal BK, Narcisco C, Kim SH, Chasen MR, Ona N, Raats J, Comia S, Lim SW, Fuerst MP, Franco MM and Kusuanco DA. (1996) The Chinese patient cohort in the International Oncology Study Group (IOSG) MM1 study: Alpha 2B Interferon in multiple myeloma. First National Congress of Hematological Oncology (Beijing). 5. Giles FJ, Villalon A, Bapsy PP, Chaimongkol B, Raafat J, Jootar S, Harryanto A, Taratom T, Sagar TG, Kim SW, Suh C, Esfahani F, Schwarer AP, Muthalib A, Song HS, Suharti C, Rapoport B, Lekhakula A, Kuchopillai V, Kim SY, Kumar R, Haron MR, Wickham NR, Intragumtornchai T, Kannan T, Cheong SK, Voges CV, Coccia-Portugal MA, Lee KB, Bellarmine L, Serdengecti S, Doyeun O, Smruti BK, Shah PM, Sotamaphan N, Jinarantana V, Aziz Z, Chuncharunee S, Prayoonwiwat W, Lim A, Leong KW, Lam KS, Leong KW, Lam KS, Ho BS, Ruff P, Kusuanco DA and Franco MM. (1996) Alpha 2B Interferon in intermediate and high grade NHL: the International Oncology Study Group (IOSG) NHL1 study. 26th Congress of the ISH (Singapore). 6. Ruff P. (1996) South African experience of the International Oncology Study Group (IOSG) MM1 study. International Oncology Study Group (IOSG) Investigators Meeting (Singapore). 7. Cheong SK, Haron MR, Lim A, Lam KS, Wah LK, Villalon A, Bapsy PP, Chaimongkol B, Raafat J, Jootar S, Harryanto A, Salim KA, Shah PM, Rapoport BL, Poovalingam V, Supandiman I, Wickham NR, Akan H, Raafat J, Uskent N, Ruff P, Franco MM, Kusuanco DA and Giles FJ. (1996) Update on the International

Oncology Study Group (IOSG) Clinical Trials. 21st Scientific meeting of Malaysian Society of Pathologists (Kuala Lumpur, Malaysia). 8. Sitas F, Carrara H, Beral V, Patel M, Ruff P, Sur R, Bezwoda W, Bourboulia D, Whitby D, Boschoff C and Weiss R. (1998) Association between HHV8, HIV, cancer and selected risk factors in South Africa. Second National AIDS Malignancy Conference (Washington, DC). 9. Davidson N, Rapoport B, Erikstein B, L'Esperance B, Ruff P , Paska W and Miller I (1998). Comparison of the efficacy and safety of Zofran Zydis with conventional Zofran tablets in the control of emesis induced by cyclophosphamide-containing chemotherapy. Multinational Association for Supportive Care in Cancer (MASSC) Congress (San Antonio,TX). 10. Ruff P, Kim A, Grimm E, Bischoff D and Chishti AH (1998). Exon skipping truncates the PDZ domain of human erythroid p55 in a patient with acute megakaryoblastic transformed chronic myeloid leukemia. ISH-EHA Combined Haematology Congress (Amsterdam, Netherlands). 11. Ruff P (2002). Long term follow-up of pegylated liposomal doxorubicin: A well tolerated and effective agent in advanced inoperable hepatocellular carcinoma. Novel Approaches in the Management of Solid Tumors Conference (Barcelona, Spain). 12. Ruff P (2003). New advances in the treatment of lymphoproliferative disorders. 4th International Conference on Cancer in Africa (AORTIC) (Accra, Ghana). 13. Fumoleau P, Campone M, Vorobiof D, Casado M, Ruff P, Khoo Kei S, Cortes-Funes H, Khalfallah S, Caroff I and Colin C (2004). Phase II study of i.v. vinflunine as second line in patients with metastatic breast cancer after anthracycline-taxane failure. 23rd Annual Meeting of American Society of Clinical Oncology (ASCO) (New Orleans, LA). 14. Nyongesa C, Ruff P, Donde B and Kotzen J (2006). Phase I study of concurrent cisplatin chemotherapy in patients with carcinoma of the cervix receiving pelvic radiotherapy. 5th International Conference on Cancer in Africa (AORTIC, Dakar, Senegal). 15. Porta C, Ruff P, Feld R, Feun L, Krzysztof GJ, Leighton J, Senico P, Gallo G and Kennealey G (2006). Results of a Phase III randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatexed (NOL) or doxorubicin (DOX). ASCO Gastrointestinal Cancers Symposium (San Francisco, CA). 16. Gish R, Porta C, Ruff P, Feld R, Feun L, Krzysztof GJ, Leighton J and Kennealey G (2006). Results of a Phase III randomized controlled study comparing the survival of patients with unresectable HCC treated with nolatexed (NOL) or doxorubicin (DOX). 41st Annual Meeting of EASL (Vienna, Austria). 17. Koehne CH, Zaluski J, Chang Chien C, Makhson A, D’Haens G, Pinter T, Lim R, Ruff P, Rougier P and van Cutsem E (2007). Cetuximab plus FOLFIRI first line in metastatic colorectal cancer (mCRC): the randomized phase III CRYSTAL trial. World Congress of Gastrointestinal Cancer (Barcelona, Spain). 18. Ruff P (2007). Treatment of chronic myeloid leukaemia in 2007. 6th International Conference on Cancer in Africa (AORTIC) (Cape Town, South Africa). 19. Dutcher J, Szczylik C, Tannir N, Benedetto P, Ruff P, Berkenblit A, Thiele A, Strahs A and Feingold J (2007). Effect of temsirolimus versus interferon-α on overall and progression free survival based on tumor histology in patients with previously untreated advanced renal cell carcinoma. International Kidney Cancer Symposium (Chicago, IL).

20. Ruff P (2008). Hepatocellular carcinoma in South Africa. Marrakesch Nexavar Symposium (Marrakesch, Morocco) 21. Ruff P (2009). Experience with anti-EGFR therapy in colorectal cancer. 1st Amgen AfME Oncology Conference (Alexandria, Egypt). 22. Ruff P (2009). Advances in the management of colorectal cancer in the 21st century. 1st Merck-Serono AfME Oncology Conference (Tunis, Tunisia). 23. Ruff P (2010). Case study in colorectal cancer. 3rd Pfizer AfME Oncology Conference (Cairo, Egypt). 24. Ruff P (2010). Advances in the management of advanced colorectal cancer in the 21st century. East Africa Oncology Experience Meeting (Mombasa, Kenya) 25. Ruff P (2010). Primary hepatocellular carcinoma in the 21st century. East Africa Oncology Experience Meeting (Mombasa, Kenya) 26. Ruff P (2010). Cancer Treatment and Research in South Africa in 21st Century. East Africa Oncology Experience Meeting (Mombasa, Kenya) 27. Ruff P (2010). Treatment of NSCLC in 2010. Pfizer AfME Oncology Advisory Board (Casablanca, Morocco). 28. Ruff P (2010). Treatment of NSCLC in 2010. Pfizer AfME Lung Cancer Advisory Board (Dubai, UAE). 29. Ruff P (2011). Role of neoadjuvant / perioperative chemotherapy in colorectal cancer liver metastases. 9th Congress of European-African Hepato-Pancreato-Biliary Association (Cape Town). 30. Nordlinger B and Ruff P (2011). Treatment with intent to resect. 3rd Amgen AfME Oncology Conference (Dubai, UAE). 31. Van Cutsem E, Tabernero J, Lakomi R, Prausona J, Ruff P, Van Hazel G, Moiseyenko V, Ferry D, MacKendricks J and Allegra C (2011). Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR). World Congress on Gastrointestinal Cancer (Barcelona, Spain). 32. Tabernero J, van Cutsem E, Lakomi R, Prausona J, Ruff P, van Hazel G, Moiseyenko V, Ferry D, McKendrick J and Allegra C (2011). Intravenous (IV) aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (mCRC): Results of a multinational phase III trial (EFC10262-VELOUR). 36th Congress of European Society of Medical Oncology, Stockhom, Sweden. 33. Allegra C, Tabernero J, Lakomy R, Prausova J, Ruff P, van Hazel G, Moiseyenko VM, Ferry DR, McKendrick J and van Cutsem E (2012). Effects of prior bevacizumab use on outcomes from the VELOUR study: A phase 3 Study of aflibercept and FOLFIRI in patients with metastatic colorectal cancer after failure of an oxaliplatin regimen. 31st Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 34. Ruff P, Ferry D, Papamichael D, Lakomy R, Prausova J, van Hazel G, Moisyenko V, Soussan-Lazard K, Bhargava P, van Cutsem E and Macarulla T (2013). Observed benefit of aflibercept in mCRC patients >65 years old: Results of a prespecified age-based analysis of VELOUR study. World Congress on Gastrointestinal Cancer (Barcelona, Spain). 35. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Błasińska-Morawiec M, Šmakal M, Williams R, Rong A, Wiezorek J, Sidhu R and Patterson S (2013). Evaluation of KRAS, NRAS, and BRAF Mutations in PRIME:

Panitumumab With FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer. World Congress on Gastrointestinal Cancer (Barcelona, Spain). 36. Price T, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Zhang K, Murugappan S and Sidhu R (2013). ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). 38th Congress of the European Society for Medical Oncology (ESMO), Amsterdam, Netherlands (LBA) 37. Chau I, Joulain F, Iqbal SU, Bridgewater J and Ruff P (2013). A VELOUR Post-Hoc Subset Analysis: Prognostic Groups and Treatment Outcomes in Patients With Metastatic Colorectal Cancer (mCRC) Treated With Ziv-Aflibercept and FOLFIRI. International society of Gastrointestinal Oncology (ISGIO) Meeting (Arlington, VA) 38. Ruff P (2013). Advances in management of metastatic colorectal carcinoma in 21st century. Grand Rounds in Medical Oncology – October 31, 2014 (Columbia University School of Medicine, New York, NY) 39. Newhall K, Price T, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Ogbagabriel S, Boedigheimer M, Sexson S, Zhang K, Murugappan S, Sidhu R (2014). Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from metastatic colorectal cancer patients treated with panitumumab or cetuximab monotherapy. World Congress on Gastrointestinal Cancer (Barcelona, Spain). 40. Price T, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Ogbagabriel S, Boedigheimer M, Sexson S, Zhang K, Murugappan S, Sidhu R, Newhall K (2014). Analysis of epidermal growth factor receptor S492R in plasma from patients with metastatic colorectal cancer after single agent panitumumab or cetuximab using droplet digital PCR. 16th Annual Scientific Meeting of Australasian Gastro-Intestinal Trials Group (Australia). 41. Ruff P (2016). Angiogenesis inhibition in colorectal cancer. GI/GU Meeting of Jordanian Oncology Society. (Amman, Jordan). 42. Ruff P and Blanchard C (2016). Cultural and regulatory barriers to pain management in low- and middle-income countries. 35th Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 43. Ruff P (2017). GIT Cancer in Africa. ESMO Africa Congress (Cape Town). Local South African Meetings: 1. Ruff P, Botha R and Meyers AM. (1986) Nocardial infections in renal transplant recipients. 16th Congress of South African Renal Society (Cape Town). 2. Ruff P, Weaving A and Derman DP. (1987) Treatment of non-small cell lung cancer with cisplatin combinations. First Congress of South African Lung Cancer Study Group (Johannesburg) 3. Rapoport B, Ruff P, Falkson G. (1988) Prognostic factors in the survival of patients with multiple myeloma. Third Congress of South African Lymphoma Study Group (Pretoria). 4. Ruff P, Coccia-Portugal A and Vorobiof D. (1988) Oral idarubicin in combination with cytosine arabinoside and etoposide in patients with acute non-lymphocytic leukaemia. Second Congress of South African Society of Medical Oncology (Pretoria). 5. Ruff P and Weaving EA. (1992) Sequential systemic therapy in the treatment of advanced prostatic carcinoma. Nineteenth Congress of Urological Association of South Africa (Sun City, South Africa).

6. Ruff P, Saragas E and Weaving EA. (1992) Blast crisis in chronic myelogenous leukaemia (CML): patterns of transformation and therapy. Fourth Congress of South African Society of Medical Oncology (Drakensberg Sun, South Africa). 7. Ruff P and Husain-Chishti A. (1992) A novel red cell protein with oncogenic implications. Fourth Congress of South African Society of Medical Oncology (Drakensberg Sun). 8. Ruff P, Saragas E and Weaving EA. (1992) Blast crisis in chronic myelogenous leukaemia: Patterns of transformation and therapy. 32nd Annual Congress of Federation of South African Societies of Pathology (Wild Coast Sun, South Africa). 9. Ruff P and Husain-Chishti A. (1992) A putative erythrocyte membrane antioncogene. 32nd Annual Congress of Federation of South African Societies of Pathology (Wild Coast Sun). 10. Ruff P, Bagg A and Papadopoulos K. (1992) Precursor T-cell lymphoma associated with HIV-1 infection. 6th Congress of SA Lymphoma Study Group (Johannesburg). 11. MacPhail AP, Ruff P, Poulos M and Weaving A. (1992) Hodgkin's disease in black patients. Sixth Congress of South African Lymphoma Study Group (Johannesburg). 12. Ruff P, Bischoff D and Chishti AH. (1993) Human erythrocyte p55: a conserved gene product with the SH3 motif is altered in CML. Fifth Congress of South African Society of Medical Oncology (Riverside Sun, Vanderbijlpark) 13. Ruff P and Chishti AH. (1993) Human erythrocyte p55: an X-linked gene product with guanylate kinase activity. Fifth Congress of SASMO (Riverside Sun) 14. Ruff P, Poulos M, Saragas E & Weaving EA. (1993) Transformed CML: Subtypes and Cytogenetics. Fifth Congress of SASMO (Riverside Sun) 15. Ruff P, Stein M & Weaving EA.(1993) Cisplatin & ifosphamide in advanced poorly differentiated carcinoma of nasopharynx. 5th Congress of SASMO (Riverside Sun) 16. Ribeiro MM, Falkson G and Ruff P. (1994) Prostate cancer: Hormonal treatment and prognosis. Urological Oncology Symposium (Cape Town, South Africa). 17. Ruff P, Long J and Mindel G. (1994) Cladribine in chronic lymphocytic leukaemia: use in fludarabine failures. Tenth Anniversary Congress of South African Lymphoma Study Group (Pretoria, South Africa). 18. Long J, Bezwoda WR, Weaving EA, Dansey R and Ruff P. (1994) Chronic lymphocytic leukaemia: The Hillbrow Hospital experience. Tenth Anniversary Congress of South African Lymphoma Study Group (Pretoria, South Africa). 19. Ruff P and Chishti AH. (1995) Human erythroid p55: a palmitoylated membrane protein with homology to the drosophila discs-large tumour suppressor protein is ubiquitously expressed and altered in blastic chronic myeloid leukaemia (CML). Sixth Congress of South African Society of Medical Oncology (Thaba Nchu Sun) 20. Ruff P, Chasen M, Long J and van Rensburg CEJ. (1995) Clofazimine in advanced unresectable hepatocellular carcinoma. Sixth Congress of South African Society of Medical Oncology (Thaba Nchu Sun) 21. Ruff P, Goedhals L, Vorobiof D, Bloch B and Paska W on behalf of the Ondansetron and Granisetron Emesis Study Group. (1995) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis. Sixth Congress of South African Society of Medical Oncology (Thaba Nchu Sun) 22. Ruff P, Rapoport B, Patel M, Chasen MR and Giles FJ on behalf of the International Oncology Study Group. (1995) Treatment of multiple myeloma patients after an objective response to induction Melphalan/ Prednisone with maintenance recombinant α 2b Interferon (Intron) alone from response to relapse vs. Intron alone

for 1 year from response vs. Intron combined with monthly pulse dexamethasone from response to relapse: an International Oncology Study Group (IOSG) Protocol. Sixth Congress of South African Society of Medical Oncology (Thaba Nchu Sun) 23. Dreosti L, Ruff P and Bezwoda WR. (1995) All-Trans Retinoic Acid in the treatment of acute promyelocytic leukaemia. Sixth Congress of South African Society of Medical Oncology (Thaba Nchu Sun) 24. Ruff P, Davidge-Pitts M and Dreosti L (1996) Cladribine in low grade lymphoproliferative disorders. 11th Congress of South African Lymphoma Study Group (Seapoint, South Africa) 25. Ruff P and Chishti AH. (1996) Human erythroid p55 is expressed in lymphoid as well as other malignancies. 11th Congress of South African Lymphoma Study Group (Seapoint, South Africa) 26. Ruff P, Rapoport BL, Wickham NR, Akan H, Raafat J, Uskent N, Patel M, Chasen MR, Raats J, Lim SW, Fuerst MM, Franco MM, Kusuanco DA and Giles FJ. (1996) Recombinant Alpha 2B Interferon as maintenance therapy in multiple myeloma: The International Oncology Study Group (IOSG) MM1 study. 11th Congress of South African Lymphoma Study Group (Seapoint, South Africa) 27. Fourie L, Villalon A, Bapsy PP, Chaimongkol B, Raafat J, Jootar S, Rapoport BL, Voges CV, Coccia-Portugal MA, Raats J, Ruff P, Lim SW, Franco MM, Kusuanco DA and Giles FJ. (1996) CHOP plus Interferon induction and Interferon maintenance versus CHOP induction alone in intermediate and high grade NHL: The International Oncology Study Group (IOSG) NHL1 study. 11th Congress of South African Lymphoma Study Group (Seapoint, South Africa) 28. Chasen MR, Goedhals L, Vorobiof DA and Ruff P. (1996) The Adcock-Ingram trial of clofazimine in relapsed lymphomas. 11th Congress of South African Lymphoma Study Group (Seapoint, South Africa) 29. Ruff P, Chishti AH and Kim A. (1997) Human erythroid p55 expression is highly conserved and is mutated in acute megakaryoblastic transformed CML. Seventh Congress of South African Society of Medical Oncology (Durban). 30. Ribeiro M, Ruff P and Falkson G. (1997) Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer. Seventh Congress of South African Society of Medical Oncology (Durban). 31. Ruff P, Chasen M, Long J and van Rensburg CEJ. (1997) Phase II study of oral clofazimine in advanced unresectable and metastatic hepatocellular carcinoma. Seventh Congress of South African Society of Medical Oncology (Durban). 32. Ruff P and Rapoport BL. (1997) Cladribine in hairy cell leukaemia, chronic lymphocytic leukaemia and other low grade lymphomas. Seventh Congress of South African Society of Medical Oncology (Durban). 33. Ruff P, Stein ME and Weaving EA. (1997) Phase II study of cisplatin and ifosfamide in advanced poorly differentiated carcinoma of the nasopharynx. Seventh Congress of South African Society of Medical Oncology (Durban). 34. Rapoport BL, Goedhals L, Ruff P, Vorobiof DA and Duckworth W. (1997) A multi-centre, double-blind, double-dummy, randomised parallel group study to compare the efficacy and safety of ondansetron tablets 8mg and ondansetron Zydis 8mg in the control of emesis and nausea induced by cyclophosphamide containing chemotherapy treatment in cancer patients. Seventh SASMO Congress (Durban). 35. Ruff P, Moodley SD, Goldberg B (1998). High dose melphalan with autologous peripheral progenitor cell rescue in systemic amyloidosis. Eighth Congress of South African Society of Medical Oncology (Cape Town, South Africa). 36. Ruff P, Chasen M, Long J and van Rensburg CEJ. (1998). Phase II study of oral

clofazimine in advanced unresectable and metastatic hepatocellular carcinoma. Eighth Congress of South African Society of Medical Oncology (Cape Town). 37. Ruff P, Kim A, Grimm E, Bischoff D and Chishti AH (1998). Exon skipping truncates the PDZ domain of human erythroid p55 in a patient with acute megakaryoblastic chronic myeloid leukemia. Eighth Congress of South African Society of Medical Oncology (Cape Town). 38. Pacella-Norman R, Sitas F, Carrara H, Patel M, Ruff P, Bezwoda W, Hale M, Sur R, Newton R and Beral V (1999). Risk factors for upper aerodigestive cancer among Black patients in Johannesburg and Soweto. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 39. Ruff P and Weaving EA. (2000). Cisplatin combinations in advanced poorly differentiated carcinoma of the nasopharynx. Ninth Congress of South African Society of Medical Oncology (Pretoria). 40. Ruff P, Moodley SD, Rapoport BL, Chasen MR, Vorobiof DA, Jacobs C and Hacking D (2000). Pegylated liposomal doxorubicin in advanced inoperable hepatocellular carcinoma. 9th Congress of South African Society of Medical Oncology 41. Ruff P and Moodley SD (2000). High dose melphalan with autologous peripheral progenitor cell rescue in primary systemic amyloidosis. Ninth Congress of South African Society of Medical Oncology (Pretoria). 42. Vorobiof DA, Chasen MR, Pienaar R, Raats J, vd Merwe A, Landers G, Rapoport B, McMichael G, Ruff P and Voges R (2000). Caelyx in the treatment of patients with advanced malignant melanoma, prostate cancer and kidney cancer. Ninth Congress of South African Society of Medical Oncology (Pretoria). 43. Rapoport BL, Vorobiof DA, Chasen MR, Ruff P, Fourie L, Mohamed R and Uys A (2000). Treatment of Philadelphia chromosome positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and YNK-01 (oral cytarabine). Preliminary results of a Phase I/II study. Ninth Congress of South African Society of Medical Oncology (Pretoria). 44. Ruff P (2000). Iressa: Hope for the future in lung cancer. Sixth Oncology Consultative Committee Meeting (Dubai, UAE). 45. Ruff P (2000). Views of a Medical Oncologist. 13th Congress of South African Lymphoma Study Group (Cape Town, South Africa) 46. Ruff P (2001). New advances in the medical management of metastatic colorectal cancer. Surgical Oncology – 18th Biennial Congress of Department of Surgery of University of Witwatersrand (Sandton) 47. Ruff P (2001). Update in the management of lymphoproliferative disorders. 41st Annual Congress of Federation of South African Societies of Pathology - South African Society of Haematology (Cape Town) 48. Ruff P and Moodley SD (2001). Primary amyloidosis: The Johannesburg experience. 41st Annual Congress of Federation of South African Societies of Pathology - South African Society of Haematology (Cape Town) 49. Kuehr T, Ruff P, Rapoport B, Jacobs C, Davidson N, Daniel F, Falk S, Boussard B, Oulid-Aissa D and Carmichael J (2001). CPT-11 and 5-Fluorouracil/folinic acid (5FU/FA) Mayo Clinic Regimen in advanced colorectal cancer as front line therapy. 10th Congress of South African Society of Medical Oncology (Johannesburg). 50. Ruff P, Moodley SD, Rapoport BL, Vorobiof DA, Maart K and Chasen MR (2001). Long term follow-up of pegylated liposomal doxorubicin: A well tolerated and effective agent in advanced inoperable hepatocellular carcinoma. 10th Congress of South African Society of Medical Oncology (Johannesburg).

51. Ruff P, Moodley SD, Slabber C and Brittan D (2001). Gemtuzumab ozogamycin (Mylotarg): A chalicheamicin labelled anti-CD33 monoclonal antibody in relapsed or refractory acute myelogenous leukaemia expressing CD33. 10th Congress of South African Society of Medical Oncology (Johannesburg). 52. Ruff P, Sebastian E and Donde B. (2001). A phase II trial of combination cisplatin and docetaxel plus radiation therapy in advanced poorly differentiated carcinoma of the nasopharynx. 10th Congress of SASMO (Johannesburg). 53. Ruff P, Moodley SD and Farrell M (2001). Simulect (Basiliximab): An interleukin-2 receptor monoclonal antibody helps control acute graft versus host disease and graft rejection in allogeneic stem cell transplantation. 10th Congress of South African Society of Medical Oncology (Johannesburg). 54. Ruff P, Moodley SD, Jacobs P, Sebastian E and Wood L (2001). Imatinib mesylate (Gleevec) in patients with chronic myelogenous leukaemia failing or intolerant of interferon-α: The South African experience. 10th Congress of South African Society of Medical Oncology (Johannesburg). 55. Moodley SD, Ruff P, Jacobs P, Sebastian E and Wood L (2001). Imatinib mesylate (Gleevec) in patients with chronic myelogenous leukaemia in accelerated or blast phase: The South African experience. 10th Congress of South African Society of Medical Oncology (Johannesburg). 56. Ruff P (2002). Iressa in NSCLC – IDEAL 2 Data. Seventh Oncology Consultative Committee Meeting (Bali, Indonesia). 57. Ruff P and Moodley SD (2003). Primary systemic amyloidosis: The Johannesburg experience. First South African Symposium on Haemopoietic Stem Cell Transplantation. (Cape Town) 58. Ruff P, Abratt R, Callaghan R, Jacobs C, Rapoport B and Landers G (2003). Iressa NSCLC Trials Assessing Combination Treatment (INTACT 1 and 2). 11th Congress of South African Society of Medical Oncology (Bloemfontein). 59. Ruff P, Moodley SD, Moodley D, Sebastian E, Loftus K and Haynes M (2003). Imatinib in patients with chronic myelogenous leukaemia failing or intolerant of interferon-α: South African experience. 11th Congress of South African Society of

Medical Oncology (Bloemfontein). 60. Kuehr T, Ruff P, Rapoport B, Jacobs C, Davidson N, Thaler J, Daniel F, Falk S, Boussard B, Oulid-Aissa D and Carmichael J (2003). CPT-11 and 5-Fluorouracil/ folinic acid (5FU/FA) Mayo Clinic Regimen in advanced colorectal cancer as front line therapy: A phase I/II study. 11th Congress of SASMO (Bloemfontein). 61. Ruff P, Moodley SD, Dreosti L and MacPhail AP (2003). Thalidomide in refractory multiple myeloma: the Johannesburg experience. 11th Congress of South African Society of Medical Oncology (Bloemfontein). 62. Moodley SD, Ruff P, Jacobs P, Moodley D, Sebastian E, Loftus K and Haynes M (2003). Imatinib in patients with chronic myelogenous leukaemia in accelerated or blast phase: The South African experience. 11th Congress of South African Society of Medical Oncology (Bloemfontein). 63. Eek R, Rapoport B, Ruff P and Callaghan R (2003). Iressa in second line NSCLC: Results of IDEAL 1 and 2. 11th Congress of South African Society of Medical Oncology (Bloemfontein). 64. Kotze D and Ruff P (2003). Accuracy of c-erbB2 testing and potential implications. 11th Congress of South African Society of Medical Oncology (Bloemfontein). 65. Kotze D, Perner Y and Ruff P (2003). Primary cutaneous lymphomas: the Johannesburg experience. 11th Congress of SASMO (Bloemfontein).

66. Ruff P (2003). Gleevec changing patients lives. Novartis Satellite Symposium: 11th Congress of South African Society of Medical Oncology (Bloemfontein). 67. Ruff P (2003). Monoclonal antibodies and other advances in the therapy of lymphoproliferative disorders. 43rd Annual Congress of Federation of South African Societies of Pathology - South African Society of Haematology (Johannesburg). 68. Ruff P (2003). New advances in cancer management. Annual Meeting of Medical Aid Advisors Group (Johannesburg). 69. Ruff P (2003). New advances in management of cancer in the elderly. Annual Meeting of Department of Radiation Oncology (Johannesburg). 70. Ruff P (2004). The role of stem cell transplantation in solid tumours. Second South African Haemopoietic Stem Cell Transplant Symposium (Johannesburg) 71. Ruff P (2004). Imatinib in chronic myelogenous leukaemia. Second South African Haemopoietic Stem Cell Transplant Symposium (Johannesburg). 72. Ruff P (2004). Signal transduction and angiogenesis in cancer. Eighth Oncology Consultative Committee Meeting (Seychelles). 73. Ruff P (2004). Signal transduction and angiogenesis in cancer. Annual Physicians Update, University of Witwatersrand (Johannesburg), 2004. 74. Ruff P (2004). Autologous stem cell transplantation in solid tumours. 15th Congress of South African Lymphoma Study Group (Cape Town, South Africa). 75. Ruff P (2004). Monoclonal antibodies in malignant disorders. 15th Congress of South African Lymphoma Study Group (Cape Town, South Africa). 76. Ruff P (2005). Advances in management of myelodysplastic syndromes. Third South African Haemopoietic Stem Cell Transplant Symposium (Cape Town). 77. Ruff P, Moodley SD, Jacobs P, Sebastian E, Woods L, Maisel C and Loftus K (2005). Imatinib in patients with chronic myelogenous leukaemia failing or intolerant of interferon-α: Long term data 6 to 48 months. 12th Congress of South African Society of Medical Oncology (KwaZuluNatal). 78. Ruff P (2005). Treatment options in primary hepatocellular carcinoma in 21st century. 12th Congress of South African Society of Medical Oncology (KZNatal). 79. Dreosti L and Ruff P (2005). Gynaecological malignancies: A retrospective view. 12th Congress of South African Society of Medical Oncology (KwaZuluNatal). 80. Ruff P (2006). Clinical practice and problem cases in CML. Fourth South African Haemopoietic Stem Cell Transplant Symposium (Johannesburg). 81. Ruff P, Gish R, Porta C, Lazar L, Feld R, Croitoru A, Feun L, Krzysztof J, Leighton J, Gallo J and Kennealey G (2007). Results of a Phase III randomized controlled study, the largest ever completed in hepatocellular carcinoma (HCC), comparing the survival of patients with unresectable HCC treated with nolatexed (NOL) or doxorubicin (DOX). 13th Congress of South African Society of Medical Oncology (Drakensberg). 82. Demetriou GS, Robertson B, Dabrowska M, Nosworthy AL and Ruff P (2007). Glivec® International Patient Assistance Program (GIPAP): South African Experience with imatinib in patients with advanced or metastatic GIST. 13th Congress of South African Society of Medical Oncology (Drakensberg). 83. Nosworthy AL, Bassa F, Demetriou GS, Louw V, Moodley SD, Schmidt A, Patel M and Ruff P (2007). Glivec® International Patient Assistance Program (GIPAP): South African experience of imatinib in chronic phase, accelerated and blast crisis CML patients. 13th Congress of South African Society of Medical Oncology (Drakensberg). 84. Ruff P, Demetriou GS, Geldenhuys D, Moodley SD and Nosworthy AL (2007). A randomized placebo-controlled, double-blind phase 2 study of docetaxel

compared to docetaxel plus zosuquidar in women with metastatic or locally recurrent breast cancer (BC) who have received one prior chemotherapy regimen. 13th Congress of South African Society of Medical Oncology (Drakensberg). 85. Penny CB and Ruff P (2007). Modulation of E-cadherin, vimentin and actin in colon cancer cells. 13th Congress of South African Society of Medical Oncology (Drakensberg). 86. Geldenhuys D and Ruff P (2007). Demographics of the South African HERA trial patients. 13th Congress of SA Society of Medical Oncology (Drakensberg). 87. Fourie SJ, Ruff P and Bender M (2007). Analysis of SAOC URC results for 2006. 13th Congress of South African Society of Medical Oncology (Drakensberg). 88. Ruff P (2007). Treatment of chronic myeloid leukaemia in 2007. Annual Physicians Update, University of Witwatersrand (Johannesburg). 89. Ruff P (2008). Primary hepatocellular carcinoma in 21st century. Annual Physicians Update, University of Witwatersrand (Johannesburg). 90. Ruff P (2008). The effect and implications of modern chemotherapy on the liver. HPBASA 2008 Consensus Meeting (Centurion). 91. Ruff P (2008). Primary hepatocellular carcinoma in 21st century. Invited lecture at University of Cape Town (Cape Town). 92. Ruff P (2009). Treatment of primary systemic AL amyloidosis. Seventh South African Haemopoietic Stem Cell Transplant Symposium (Johannesburg). 93. Ruff P (2009). Biomarkers in the treatment of cancer. First University of Witwatersrand Surgical Oncology Congress (Johannesburg). 94. Ruff P (2010). Lymphoma: a clinician’s perspective. IAEA PET/CT Workshop (Midrand). 95. Ruff P (2010). Treatment of CML in 2010. Novartis CML Scientific Forum (Johannesburg). 96. Milner B, Gibbon V, Penny C and Ruff P (2010). Isolation and Characterization of Colon Cancer Stem Cells and the Effects of Epigenetic Modulation on Pluripotent Markers. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 97. Ruff P (2011). Advances in the management of advanced colorectal cancer in 21st Century. Annual EHPBA Meeting (Cape Town). 98. Ruff P (2011). Impact of newer oncology treatments in GIT malignancies. Second University of Witwatersrand Multidisciplinary Oncology Congress (Johannesburg). 99. Ruff P, Lombaard S, Demetriou GS, Nosworthy A and Willem P (2011). Local experience with imatinib and nilotinib in CML patients. 15th Congress of South African Society of Medical Oncology (Sun City). 100. Hansa S, Hemus A, Demetriou GS, Moodley SD and Ruff P (2011). Are routine South African her-2 testing methods sufficiently accurate for true her-2 prediction? 15th Congress of South African Society of Medical Oncology (Sun City). 101. Sze Wai Chan, Maske C and Ruff P (2011). EGFR Mutations in NSCLC patients in South Africa. 15th Congress of South African Society of Medical Oncology (Sun City). 102. Ruff P, Nosworthy A, Demetriou G, Moodley SD, Hemus A and Hansa S (2011). Local experience with anti-EGFR therapy in newly diagnosed metastatic colorectal cancer (mCRC): CRYSTAL & PRIME studies. 15th Congress of South African Society of Medical Oncology (Sun City). 103. Ruff P (2012). Advances in treatment of advanced HPB malignancies in 21st century – where are we going? HPBASA 2012 Meeting (Centurion). 104. Ruff P, Ferry D, Lakomy R, Prausova J, van Hazel G, Moiseyenko V,

McKendrick J, van Cutsem E and Macarulla T (2013). Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. 16th Congress of South African Society of Medical Oncology (Drakensberg). 105. Ruff P (2013). Regulatory Affairs – Role of MCC. 16th Congress of South African Society of Medical Oncology (Drakensberg). 106. Ruff P (2016). Advances in chemotherapy of lung cancer since 1980s. South African Thoracic Society (SATS) Meeting (Four Ways). 107. Ruff P (2016). Angiogenesis inhibition in gastrointestinal cancer. Surgical Biennial (University of Witwatersrand) 108. Penny CB, Omar A and Ruff P (2016). SHH Pathway Signalling in Cancer Stem Cells. Keynote Address: South African Society for Molecular Biology and Biochemistry Conference (East London).

SESSIONS CHAIRED AT CONFERENCES:

1. University of Cape Town Lung Cancer Workshop (Cape Town) 1993. 2. 5th Congress of South African Society of Medical Oncology (Riverside Sun) 1993. 3. 10th Congress of South African Lymphoma Study Group (Pretoria) 1994. 4. 6th Congress of South African Society of Medical Oncology (Thaba Nchu) 1995. 5. 7th Congress of South African Society of Medical Oncology (Durban) 1997. 6. 8th Congress of South African Society of Medical Oncology (Cape Town) 1998. 7. 11th Congress of South African Lymphoma Study Group (Cape Town) 1998. 8. 9th Congress of South African Society of Medical Oncology (Pretoria) 2000. 9. 41st Annual Congress of Federation of South African Societies of Pathology - South African Society of Haematology (Cape Town) 2001. 10. Annual Physicians Update, University of Witwatersrand (Johannesburg) 2001. 11. 10th Congress of SASMO/SASCRO (Johannesburg) 2001. 12. 1st Roche Oncology Own Event (Ballito) 2002. 13. European School of Oncology Breast Cancer Workshop (Johannesburg) 2002. 14. First South African Symposium on Haemopoietic Stem Cell Transplantation (Cape Town) 2003. 15. 11th Congress of SASMO/SASCRO (Bloemfontein) 2003. 16.Tema Medical Satellite Symposium at Eleventh Congress of South African Society of Medical Oncology (Bloemfontein) 2003. 17. Annual Physicians Update, University of Witwatersrand (Johannesburg) 2003. 18. 4th International Conference on Cancer in Africa (Accra, Ghana) 2003. 19. 2nd South African Haemopoietic Stem Cell Transplantation Symposium (Johannesburg) 2004. 20. 8th Oncology Consultative Committee Meeting (Seychelles) 2004. 21. 2nd Roche Oncology Own Event (Kleinmond) 2004. 22. European School of Oncology Upper GIT Cancer Workshop (Johannesburg) 2004. 23. 15th Congress of South African Lymphoma Study Group (Cape Town) 2004. 24. 3rd South African Haemopoietic Stem Cell Transplantation Symposium (Cape Town) 2005. 25. 12th Congress of SASMO/SASCRO (KwaZuluNatal), 2005. 26. 4th South African Haemopoietic Stem Cell Transplantation Symposium (Johannesburg) 2006.

27. European School of Oncology Gynaecological Cancer Workshop (Johannesburg) 2006. 28. 3rd Roche Oncology Own Event (Livingstone, Zambia) 2006. 29. 5th South African Haemopoietic Stem Cell Transplantation Symposium (Cape Town) 2007. 30. 13th Congress of SASMO/SASCRO (Drakensberg) 2007. 31. 6th South African Haemopoietic Stem Cell Transplantation Symposium (Durban) 2008. 32. 4th Roche Oncology Own Event (Kleinmond) 2008. 33. 14th Congress of SASMO/SASCRO (Cape Town) 2009. 34. 1st University of Witwatersrand Surgical Oncology Congress (Johannesburg) 2009. 35. 7th South African Haemopoietic Stem Cell Transplantation Symposium (Johannesburg) 2009. 36. 2nd Amgen AfME Oncology Conference (Istanbul, Turkey) 2010. 37. East Africa Oncology Experience Meeting (Mombasa, Kenya) 2010 38. 5th Roche Oncology Own Event (Cape Town), 2010. 39. 4th Annual Haematology/Oncology Symposium (Cape Town), 2010. 40. 1st Pfizer AfME Lung Cancer Advisory Board Meeting (Dubai, UAE) 2010. 41. 2nd University of Witwatersrand Multidisciplinary Oncology Congress (Johannesburg) 2011. 42. 9th South African Haemopoietic Stem Cell Transplantation Symposium (Johannesburg) 2011. 43. 3rd Merck-Serono AfME Oncology Conference (Cape Town) 2011. 44. 4th Pfizer Africa & Middle East Oncology Forum (Istanbul, Turkey) 2011. 45. 15th Congress of South African Society of Medical Oncology (Sun City) 2011. 46. 6th Roche Oncology Own Event (Cape Town), 2012. 47. 16th Congress of South African Society of Medical Oncology (Drakensberg) 2013. 48. 3rd University of Witwatersrand Multidisciplinary Oncology Congress (Johannesburg) 2014. 49. Annual Physicians Update, University of Witwatersrand (Johannesburg) 2014. 50. Annual Physicians Update, University of Witwatersrand (Johannesburg) 2015. 51. Annual Physicians Update, University of Witwatersrand (Johannesburg) 2016. 52. ESMO Africa Congress (Cape Town) 2017. CONFERENCE POSTERS: International Meetings: 1. Ruff P, Derman D, Weaving A & Bezwoda W (1987) Systemic therapy of advanced prostatic carcinoma. 3rd International Congress on Hormones & Cancer (Hamburg). 2. Jarolim P, Ruff P, Coetzer TL, Prchal J, Ballas S, Poon S, Brabec V and Palek J. (1990) A subset of patients with dominantly inherited hereditary spherocytosis has a marked deficiency of the anion transport protein. 32nd Annual Meeting of American Society of Hematology (Boston, MA). 3. Husain-Chishti A, Ruff P and Speicher DW. (1991) Molecular identification of a major palmitoylated erythrocyte membrane protein containing the SH-3 (src homology-3) motif. Gordon Conference on Red Blood Cells (New Hampshire, USA).

4. Ruff P, Poulos M, Saragas E and Weaving EA. (1993) Transformed CML: Patterns and Therapy. Seventh European Conference on Clinical Oncology and Cancer Nursing (Jerusalem, Israel). 5. Ruff P, Stein M and Weaving EA. (1994) Cisplatin and ifosphamide in advanced poorly differentiated carcinoma of the nasopharynx. 16th International Cancer Congress (New Delhi, India). (Best Poster of Session). 6. Ruff P, Stein M and Weaving EA. (1995) Cisplatin and ifosfamide in advanced poorly differentiated carcinoma of the nasopharynx. 14th Annual Meeting of American Society of Clinical Oncology (Los Angeles, CA). 7. Look RM, Supandiman I, Suh C, Muthalib A, Suharti C, Rapoport BL, Tan P, Chen YC, Salim KA, Harrayanto A, Radheshyam D, Suwansela N, Ruff P, Lim SW, Kusuanco DA and Giles FJ. (1995) Treatment of multiple myeloma patients after an objective response to induction Melphalan/ Prednisone with maintenance recombinant α 2b Interferon (Intron) alone from response to relapse vs. Intron alone for 1 year from response vs. Intron combined with monthly pulse dexamethasone from response to relapse: an International Oncology Study Group (IOSG) Protocol. Ninth Symposium of Molecular Biology in Hematopoiesis and Treatment for Leukemias and Lymphomas (Genoa, Italy). 8.Harrayanto A, Supandiman I, Suh C, Muthalib A, Suharti C, Rapoport BL, Salim KA, Tan P, Chen YC, Radheshyam D, Suwansela N, Sagar TG, Ruff P, Kusuanco DA and Giles FJ. (1995) An International Oncology Study Group (IOSG) Protocol: Maintenance therapy in de novo multiple myeloma patients after an objective response to induction Melphalan/Prednisone with recombinant α 2b Interferon

(Intron) alone from response to relapse vs. Intron alone for 1 year from response vs. Intron combined with monthly pulse dexamethasone from response to relapse. 8th Congress of the Asia-Pacific Division of ISH (Brisbane, Australia.). 9. Giles F, Wickham NR, Akan H, Raafat J, Uskent N, Supandiman I, Ruff P, Suharti C, Suh C, Muthalib A, Tan P, Kochupillai V, Rapoport BL, Lee KB, Parikh PM, Salim KA, Harryanto A, Radheshyam D, Sagar TG, Lekhakula A, Thamprasit T, Kang JH, Suwansela S, Smurti BK, Kim SY, Anggraeni E, Sumantri R, Ragnuhardi D, Gonzaga M, Gopal BK, Narcisco C, Kim SH, Chasen MR, Ona N, Raats J, Comia S, Lim SW, Fuerst MP, Franco MM and Kusuanco DA. (1996) Maintenance recombinant alpha 2B Interferon in multiple myeloma: the International Oncology Study Group (IOSG) MM1 study. 26th Congress of the International Society of Haematology (Singapore). 10. Ruff P, Chasen MR, Long JEH and van Rensburg CEJ. (1996) Phase II study of clofazimine in advanced unresectable hepatocellular carcinoma (HCC). 21st Congress of European Society of Medical Oncology (Vienna, Austria). 11. Rapoport Bl, Wickham NR, Akan H, Raafat J, Uskent N, Supandiman I, Ruff P, Suharti C, Suh C, Ho CH, Muthalib A, Tan P, Kochupillai V, Lee KB, Parikh M, Salim KA, Harryanto A, Radheshyam RD, Sagar TG, Lekhakula A, Thamprasit T, Chen YC, Kang JH, Suwansela N, Smurti BK, Tian D, Kim SY, Anggraeni E, Wang PM, Sumantri R, Ragnuhardi D, Gonzaga M, Gopal BK, Narcisco C, Kim SH, Chasen MR, Ona N, Raats J, Chao TY, Comia S, Lim SW, Fuerst MP, Franco MM, Kusuanco DA and Giles F. (1996) Phase III study of recombinant α2 interferon as maintenance

therapy in patients with de novo multiple myeloma: The IOSG MM1 Study. Multiple myeloma: Advances in biology and treatment (Vienna, Austria). 12. Giles FJ, Rapoport BL, Suhartu C, Ruff P, Kochupillai V, Akan H, Wickham NR, Lim SW, Franco MM, Kusuanco DA and Fuerst MP. (1996) Update on the International Oncology Study Group (IOSG) MM1 study: the use of recombinant α2b interferon as maintenance therapy in de novo multiple myeloma. Second

International Cancer Conference (Lahore, Pakistan) 13. Ruff P, Moodley SD, Rapoport BL, Chasen MR, Vorobiof DA, Jacobs C and Hacking D (2000). Pegylated liposomal doxorubicin in advanced inoperable hepatocellular carcinoma. 25th Congress of European Society of Medical Oncology (Hamburg, Germany). 14. Ruff P, Moodley SD, Rapoport BL, Vorobiof DA, Maart K and Chasen MR (2001). Long term follow-up of pegylated liposomal doxorubicin: A well tolerated and effective agent in advanced inoperable hepatocellular carcinoma. 20th Annual Meeting of American Society of Clinical Oncology (San Francisco, CA). 15. Kuehr T, Ruff P, Rapoport B, Jacobs C, Davidson N, Daniel F, Falk S, Boussard B, Oulid-Aissa D and Carmichael J (2001). CPT-11 and 5-Fluorouracil/folinic acid (5FU/FA) Mayo Clinic Regimen in advanced colorectal cancer as front line therapy. 11th European Conference on Clinical Oncology (Lisbon, Portugal). 16.Gish R, Ruff P, Feld R, Porta C, Hossfeld D, Tuan B, Geddes C, Knox J, Schmiegel W, Palmeri S, Garcia-Vargas J, Suplick G, Senico P and Gallo J (2003). Safety of the phase III randomised study of Thymitaq® vs. doxorubicin in unresectable HCC: ETHECC Trial vs. safety of phase II program with Thymitaq®. American Association for the Study of Liver Disease Single Topic Conference (Atlanta, GA). 17. Gish R, Porta C, Ruff P, Feld R, Feun L, Krzysztof GJ, Leighton J and Kennealey G (2006). Results of a Phase III randomized controlled study comparing the survival of patients with unresectable HCC treated with nolatexed (NOL) or doxorubicin (DOX). Shanghai- Hong Kong International Liver Congress (Shanghai, China). 18. Penny C and Ruff P (2006). Modulation of e-cadeherin and actin in colon cancer cells. 46th Annual Meeting of American Society for Cell Biology (San Diego, CA). 19. Woodward V, Penny CB, Ruff P and Strkalj G (2006). Bone extraction from the intercondylar fossa of the femur for DNA studies. 15th Congress of European Anthropological Association (Budapest, Hungary). 20. Dutcher J, Szczylik C, Tannir N, Benedetto P, Ruff P, Berkenblit A, Thiele A, Strahs A and Feingold J (2007). Correlation of survival and tumor histology for previously untreated patients with advanced renal cell carcinoma (RCC) receiving temsirolimus or interferon-α. 26th Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 21. Gibbon VE, Štrkalj G, Ruff P and Penny CB (2008). Novel methods of molecular sex determination utilising the amelogenin gene. Annual Meeting of American Association of Physical Anthropologists (AAPA) (Columbus, OH). 22. Gibbon VE, Štrkalj G, Ruff P and Penny CB (2008). Sex determination of Chinese indentured labourers from the gold mining era in the early 1900s in South Africa. 9th International Conference on Ancient DNA (Pompeii, Italy). 23. Penny CB, Gibbon V, Swanson R and Ruff P (2008). Modulation of the hedgehog pathway in colon cancer cells. 48th Annual Meeting of American Society for Cell Biology. (San Francisco, CA) 24. Siena S, Tabernero J, Cunningham D, Koralewski P, Ruff P, Rother M, Johnson CW, Zhang A, Gansert J and Douillard JY (2010). Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st line treatment for metastatic colorectal cancer: PRIME trial analysisby EGFR tumor staining. 29th Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL) 25. Cunningham D, Ruff P, Rother M, Siena S, Tabernero J, Cassidy J, Koralewski P, Jassem J, Rivera F, Kocakova I, Rogowski W, Canon JL, Yanez E, Johnson CW, Zhang A, Gansert J, Xu F and Douillard JY (2010). Randomised open-label phase 3

study (PRIME) of panitumumab plus FOLFOX4 compared with FOLFOX4 alone as 1st line treatment of metastatic colorectal cancer: analysis of efficacy by EGFR status and severity of skin toxicity. 12th Australian GI Trials Group Annual Meeting (Adelaide, Australia). 26. Milner B, Penny C, Gibbon V and Ruff P (2010). Isolation and Characterization of Colon Cancer Stem Cells and the Effects of Epigenetic Modulation on Pluripotent Markers.50th Annual meeting of the American Society for Cell Biology (Philadelphia) 27. Penny C, Milner B, Gibbon V, Wood L and Ruff P (2010). Thalidomide inhibits cell migration and invasion in colon cancer cells. 50th Annual meeting of the American Society for Cell Biology (Philadelphia, USA). 28. Ruff P, Tabernero J, Lakomy R, Prausova J, van Hazel G, Moiseyenko VM, Ferry DR, McKendrick J and van Cutsem E (2013). Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. 10th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 29. Ruff P, Tabernero J, Lakomy R, Prausova J, van Hazel G, Moiseyenko VM, Ferry DR, McKendrick J and van Cutsem E (2013). Analysis of overall survival and safety during the course of the phase III VELOUR trial comparing FOLFIRI and ziv-aflibercept or placebo in mCRC patients who progressed on prior oxaliplatin treatment. 32nd Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 30. Oliner K, Douillard JY, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I; Ruff P, Błasińska-Morawiec M, Smakal M, Rong A, Wiezorek J, Sidhu R, Patterson SD and Williams R (2013). Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). 32nd Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 31. Douillard JY, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I; Ruff P, Smakal M, Canon JL, Rother M, Oliner K, Tian Y and Sidhu R (2013). Overall survival analysis from PRIME: Randomized phase III study of panitumumab with FOLFOX4 for first line mCRC. 32nd Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 32. Ruff P, Ferry D, Papamichael D, Lakomy R, Prausova J, van Hazel G, Moisyenko V, Soussan-Lazard K, Bhargava P, van Cutsem E and Macarulla T (2013). Observed benefit of aflibercept in mCRC patients over 65 years old: Results of a prespecified age-based analysis of VELOUR study. International Society of Gastrointestinal Oncology Meeting (Arlington, VA). 33. Price T, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Sidhu R and Murugappan S (2015). Randomized phase 3 study of panitumumab vs cetuximab in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia in ASPECCT. 12th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 34. Price T, Newhall K, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Boedingheimer M, Zhang K, Sidhu R and Murugappan S (2015). Prevalence and outcomes of patients with EGFR S492R ectodomain mutations in ASPECCT: panitumumab vs cetuximab in patients with

chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). 12th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 35. Siena S, Taberneo J, Bodoky G, Cunningham D, Rivera F, Ruff P, Canon JL, Koukakis R, Terwey JH and Douillard JY (2015). Quality of life during first-line treatment with FOLFOX4 with or without panitumumab in RAS Wild-Type metastatic colorectal carcinoma in RAS Wild-Type metastaic colorectal carcinoma. 12th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 36. Chan SW, Maske CP and Ruff P (2015). EGFR mutations in NSCLC in South Africa. European Lung Cancer Conference. (Geneva, Switzerland). 36. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Zhang K, Sidhu R and Murugappan S (2015). Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab vs cetuximab in chemorefractory WT KRAS exon 2 mCRC. 34th Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 37. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AV, Thomas A, Tjulandin S, Zhang K, Sidhu R and Murugappan S (2015). Randomized phase 3 study of panitumumab vs cetuximab in chemorefractory WT KRAS exon 2 mCRC: outcomes by hypomagnesemia in ASPECCT. 34th Annual Meeting of American Society of Clinical Oncology (ASCO) (Chicago, IL). 38. Price TJ, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, X Guan, Hoang T, Hei Y and Peeters M (2015). Efficacy outcomes by severity of skin toxicity from ASPECCT: randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). 40th Congress of the European Society for Medical Oncology (ESMO), Vienna, Austria. 39. Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Hoang T and Price T (2016). Outcomes by Hypomagnesemia in the Randomized Phase 3 ASPECCT Trial of Patients With Chemorefractory Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer. 13th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 40. Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Hoang T and Price T (2016). Efficacy of Panitumumab vs Cetuximab in Patients With Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer Treated With Prior Bevacizumab: Results From ASPECCT. 13th Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Symposium (San Francisco, CA). 41. Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Guan X, Hoang T and Price T (2016). Efficacy of Panitumumab vs Cetuximab in Patients With Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer Treated With Prior Bevacizumab: Results From ASPECCT. 35th Annual American Society of Clinical Oncology (ASCO) (Chicago, IL). 42. Raymond E, Kulke MH, Qin S, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu J, Racz K, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Fernandez KC, Rosbrook B and Fazio N (2016). The Efficacy and Safety of Sunitinib in Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors. North American Neuroendocrine Tumor Society (NANETS) Symposium (Jackson Hole, WY). 43. Price TJ, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, X Guan, Hoang T, Hei Y and Peeters M (2016). Final results and outcomes by prior

bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. 41st Congress of the European Society for Medical Oncology (ESMO), Copenhagen, Denmark. 44. A Khan, K Subramanian, J Kandhavelu, P Ruff, C Penny (2016). Levamisole affects the expression of epithelial to mesenchymal transition markers in colorectal cancer cells. Frontiers in Cancer Science (National University of Singapore). 45. J Kandhavelu, K Subramanian, A Khan, P Ruff, C Penny (2016). The effect of epigenetic drugs on cell cycle phase and oncogenic microRNA expression in colon cancer cell lines. Frontiers in Cancer Science (National University of Singapore). 46. K Subramanian, J Kandhavelu, A Khan, P Ruff, C Penny (2016). Effect of anticancer drugs on the expression of miRNA-155 and its target gene, ZNF 367 in triple negative breast cancer cells. Frontiers in Cancer Science (National University of Singapore). Local South African Meetings: 1. Rapoport B, Chasen M, Ruff P and Falkson G. (1988) Ifosphamide alternating with etoposide and cisplatin in the treatment of small cell lung cancer. Second Congress of SASMO (Pretoria). 2. Panz V, Ruff P, Raal FJ and Joffe BI. (1994) Mutations of the Insulin Receptor Beta-Subunit in Lipoatrophic Diabetes Mellitus: A Preliminary Report. 30th Congress of Society of Endocrinology, Metabolism and Diabetes of Southern Africa (Wilderness, South Africa). 3. Panz V, Ruff P, Joffe BI, Kedda M-A and Seftel HC. (1995) Polymorphisms in the tyrosine kinase domain of the insulin receptor gene detected by single strand conformation polymorphism analysis in South African black and white subjects with and without NIDDM. 14th Congress of Society of Endocrinology, Metabolism and Diabetes of Southern Africa (Bloemfontein). 4. Ruff P and Weaving EA. (1995) Cisplatin and ifosfamide in advanced poorly differentiated carcinoma of the nasopharynx. Sixth Congress of SASMO (Thaba Nchu Sun, South Africa). 5. Ribeiro M, Ruff P and Falkson G. (1995) Prognostic factors in hormonally treated metastatic prostate cancer. Sixth Congress of SASMO (Thaba Nchu Sun). 6. Ruff P, Kim A, Grimm E, Bischoff D and Chishti AH (1999). Exon skipping truncates the PDZ domain of human erythroid p55 in acute megakaryoblastic chronic myelogenous leukemia. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 7. Carrara H, Pacella-Norman R, Sitas F, Patel M, Ruff P, Bezwoda W, Sur R, Bull D and Beral V (1999). Injectable progestogen contraceptive use and the risk of breast cancer in Black South African women in Johannesburg. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 8. Sitas F, Carrara H, Newton R, Reeves D, Patel M, Ruff P, Bezwoda W, Hale M, Jentsch U, Retter E, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff D and Weiss R (1999). The seroepidemiology of human herpes virus 8 (HHV-8) and its relation to Kaposi's sarcoma in South Africa. University of Witwatersrand Faculty of

Health Sciences Research Day (Johannesburg). 9. Lehoka J and Ruff P (2001). An attempt to identify the cause relative to the perceived high incidence of aplastic anaemia as seen in patients in the Adult Haematolgy Clinic at the Johannesburg Hospital. 10th Congress of SASMO (Johannesburg). 10. Ruff P and Guidozzi F (2001). Successful twin pregnancy following interferon-α and autologous stem cell transplantation for chronic myelogenous leukaemia. 10th Congress of SASMO (Johannesburg). 11. Lehoka J and Ruff P (2003). Short study on laxatives and colorectal cancer. 11th Congress of SASMO (Bloemfontein). 12. Penny C, MacPhail AP and Ruff P (2005). Thalidomide treatment alters cell morphology of colon cancer cell lines. 12th Congress of SASMO (KwaZuluNatal). 13. Penny C, Milner B, Gibbon V, Wood LA and Ruff P (2010). Thalidomide inhibits cell migration and invasion in colon cancer cells. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 14. Govan D, Gibbon V, Penny C and Ruff P (2010). Bioinformatic prediction of putative microRNA targets for further evaluation in colorectal cancer. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 15. Moodley N, Gibbon V, Penny C and Ruff P (2010). The effects of epigenetic modulation on the expression of pluripotent stem cell markers in colon cancer cells. University of Witwatersrand Faculty of Health Sciences Research Day (Johannesburg). 16. J Kandhavelu, K Subramanian, A Khan, P Ruff, C Penny (2016). Effect of SAHA, a Histone Deacteylase Inhibitor on Colon Cancer Cell Lines and Its Role on Oncogenic MicroRNA Expression. South African Society for Molecular Biology and Biochemistry Conference (East London). 17. Subramanian K, Kandhavelu J, Khan A, Ruff P and Penny C (2016). Zebularine and Paclitaxel alter MicroRNA Expression Levels in Breast Cancer Cell Lines. South African Society for Molecular Biology and Biochemistry Conference (East London). 18. A Khan, K Subramanian, J Kandhavelu, P Ruff and C Penny (2016). Levamisole Reduces the Epithelial to Mesenchymal Transition in Colorectal Cancer Cells. Poster Presentation, South African Society for Molecular Biology and Biochemistry Conference (East London). 19. Kandhavelu J, Ruff P and Penny C (2016). Histone deacetylase inhibitors: role in oncogenic miRNA expression in colon cancer cell lines Poster presentation, Faculty of Health Sciences Research Day (University of the Witwatersrand). 20. K Subramanian, P Ruff and C Penny (2016). Effect of the demethylation agent Zebularine and the microtubule disruptor Paclitaxel on microRNA expression levels in breast cancer cell lines. Faculty of Health Sciences Research Day (University of the Witwatersrand).